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The Role of BMP Signaling in Mediating Stimulatory Effects of FGF-FGFR Signaling on
Odontoblast Differentiation in Dental Pulp

Karen Sagomonyants, D.M.D., Ph.D.

University of Connecticut, 2017

Odontoblast differentiation is dependent on multiple signaling molecules, including growth
factors stored in the extracellular dentin matrix. Our previous studies have demonstrated that
Fibroblast Growth Factor 2 (FGF2) exerted stage-specific effects on odontoblast differentiation
in primary dental pulp cultures. FGF2 stimulated differentiation of functional odontoblasts
expressing high levels of Dmp1 from early progenitors but inhibited the terminal differentiation
of functional odontoblasts to fully differentiated odontoblasts expressing high levels of Dspp.
These stimulatory effects involved activation of FGFR and ERK1/2, and increased levels of
expression of Bmp2, Runx2, and Osx (components of BMP signaling) suggesting the
involvement of BMP signaling in FGF2-induced Dspp expression. Therefore, the overall goal of
the studies outlined in this thesis was to examine the role of BMP signaling in stimulatory effects
of FGF signaling on odontoblast differentiation of dental pulp cells. We showed that BMP2 did
not affect the extent of mineralization but rapidly (within ~12-24 hrs) stimulated expression of
Dspp and intensity of DSPP-Cerulean transgene in a concentration-dependent manner without
affecting the percentage of DSPP-Cerulean+ odontoblasts. In contrast to Dspp, BMP2 rapidly
(within ~24-48 hrs) decreased expression of Dmp1, Bsp, DMP1-mCherry, and BSP-GFP in a

x

Karen Sagomonyants, University of Connecticut, 2017

concentration-dependent manner. Inhibition of the BMP and FGF signaling pathways by noggin
and SU5402, respectively, did not have marked effects on the extent of mineralization but
decreased expression of Dspp stimulated by these growth factors. These inhibitory effects were
long-lasting and observed up to 14 days after removal of the growth factors. Additional
experiments in primary bone marrow stromal cells cultures demonstrated that early and limited
exposure to BMP2 did not affect mineralization but decreased expression of Dmp1, Bsp, and
respective transgenes. Taken together, our results demonstrated that activation of the canonical
BMP signaling pathway during the proliferation phase of in vitro growth resulted in significant
increases in the expression of Dspp, and these increases were mediated via reciprocal interaction
of the BMP and FGF signaling pathways. These data will further elucidate the perspectives of
using both FGF2 and BMP2 in dentin regeneration applications.
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CHAPTER I. Introduction
Tooth Development and Odontoblast Differentiation

Odontoblast differentiation during in vivo tooth development is a complex and multistep
process, involving epithelial-mesenchymal interactions 1,2. During early stages of dentinogenesis,
cells originating from the neural crest migrate toward the paraxial mesenchyme of the first
branchial arch, where they contribute to the formation of tooth buds. These neural crest-derived
dental papilla cells receive signals from dental epithelium and become preodontoblasts.
Preodontoblasts undergo the minimum number of cell cycles before they become competent to
respond to external stimuli, such as growth factors or trauma, and become polarized
odontoblasts. In addition to morphological changes, these cells undergo functional changes, as
they are the first cells within the odontoblast lineage to secrete Type I collagen (a major
component of unmineralized predentin) as well as Types V and VI collagen 1,3.

During further differentiation, polarized odontoblasts differentiate into functional (or
secretory) odontoblasts, which in addition to Type I collagen start secreting various noncollagenous components (NCPs) of unmineralized predentin, including members of the
SIBLING family, such as BSP, DMP1, and DSPP. Functional odontoblasts eventually become
fully differentiated (or mature) odontoblasts secreting mineralized dentin matrix 1,3,4.

Dentin

Dentin is a mineralized tissue resulting from the formation of a specific extracellular

1

matrix (ECM) by the highly polarized postmitotic odontoblasts located at the periphery of the
dental pulp 5. Dentin is first deposited as a layer of unmineralized matrix called predentin, which
lines its innermost (pulpal) portion. Predentin is composed primarily of Type I collagen and is
biochemically similar to osteoid in bone. Predentin gradually undergoes mineralization, as
various NCPs are incorporated into the mineralization front, forming mineralized dentin matrix 6.
This is a matrix-controlled process, which requires the presence of Type I collagen serving as a
scaffold for NCPs 3.

Mature dentin is composed of approximately 70% inorganic (mineral) material, 20%
organic material and 10% water by weight (40-45%, 30% and 20-25% by volume, respectively).
This makes dentin slightly harder than bone and softer than enamel 3,6.

The organic component consists primarily of Type I collagen, which constitutes
approximately 90% of all dentin proteins, and is one of the earliest markers of odontoblast
differentiation 3,6. Type I collagen by itself does not induce mineralization, however, it serves as
an organic scaffold to retain various NCPs and accommodate a large proportion (~56%) of the
mineral in the holes and pores of the fibrils 6-8. In addition to Type I collagen, small amounts of
Types III and V collagen (~3%) are also present in the dentin of very young animals or during
defective collagen synthesis 3. The importance of the correct collagen structure in dentin is seen
in patients with dentinogenesis imperfecta (DGI) type I caused by mutations in the Type I
collagen gene, which clinically resembles DGI type II and III caused by Dspp mutations 6,9-11.

Inorganic component of dentin is primarily represented by hydroxyapatite (HA)

2

[Ca5(PO4)3OH] 6. The mineral phase appears first within the matrix vesicles as single crystals
seeded by phospholipids of the vesicle membrane. These crystals grow rapidly and later fuse
with adjacent crystals to form a continuous layer of the mineralized matrix. Following mineral
seeding, NCPs produced by odontoblasts regulate mineral deposition 6.

Dental Pulp

Dental pulp is a connective tissue that resides within the pulp chamber of a tooth. Dentin
is an immediate tissue that contacts the dental pulp cells. Due to slow but continuous deposition
of physiological secondary dentin, the space occupied by pulp is gradually reduced. Thus, the
communication between pulp and periapical tissues occurs only via the apical foramen, which
contains blood vessels and nerves

12

. Although dental pulp shares many properties with other

connective tissues in the body, its unique localization imposes several special constrains on its
development, maintenance and response to injury 13.

Several zones within the pulp can be distinguished based on their location. Subjacent to
the layer of odontoblasts is the cell-free zone (also called zone of Weil), which is the area that is
relatively free of cells. More deeply, there is a cell-rich zone, which is relatively rich in cells
(fibroblasts, undifferentiated mesenchymal cells, immune cells, etc.) and blood capillaries. Due
to the presence of undifferentiated cells that are frequently occupying the perivascular area, this
zone is presumably the source of cells that will give rise to newly formed odontoblast-like cells
after injury or death of primary odontoblasts. Finally, pulp proper (or pulp core) is also rich in
cells (fibroblasts, undifferentiated mesenchymal cells, immune cells) and blood vessels

3

13

.

Decreased numbers of pulp cells are observed with aging in humans and rodents 12.

Besides cells and blood vessels, dental pulp contains extracellular matrix, which typically
includes various proteins, such as collagen, glycosaminoglycans, proteoglycans, and fibronectin
12,13

. An important feature of dental pulp is the lack of DSP and DPP proteins, suggesting the

lack of mature odontoblasts 12.

The considerable capacity of dental pulp for dentin regeneration and repair and
identification of stem/progenitor cells in dental pulp capable of giving rise to new odontoblastlike cells make dental pulp cells a valuable model for examining the mechanisms regulating the
sequential steps involved in odontoblast differentiation.

Bone Morphogenetic Proteins (BMPs)

Definition and Classification:
First indirect evidence of the existence of BMPs was provided by Urist’s rabbit studies in
1965

14

, but it was not until the 1970s that their osteogenic potential was characterized

15,16

.

These molecules were called “bone morphogenetic proteins” due to their ability to target a group
of cells capable of responding to their osteogenic-inducing effects. To date, BMPs represent the
largest subfamily of the transforming growth factor β (TGFβ) superfamily of growth factors.
Currently, over 25 distinct BMPs have been identified

17,18

, which can be classified into four

subfamilies: (i) BMP2 and 4; (ii) BMP5, 6, 7, 8a, and 8b; (iii) BMP9 and 10; and (iv) BMP12,

4

13, and 14 19,20. These proteins are surprisingly conserved among various species, and during 700
million years of evolution, the increased number of components of BMP signaling occurred as a
result of genomic duplications or chromosomal translocation

21,22

. Although in more primitive

species, such as Drosophila, BMPs control dorsoventral body patterning and imaginal disk
formation, and mammalian BMP functions are much more diverse, these molecules share at least
75% homology with each other 23.

In humans, genes encoding BMPs are located on several chromosomes. BMP proteins
and the respective receptors are expressed during early embryonic development and continue
during later organogenesis

24

. These proteins are involved in various physiological events,

including regulation of bone formation, kidney and heart development, vasculogenesis, glucose
metabolism, development of oocytes and spermatogenesis, and others 17,25. Therefore, deletion of
BMPs, such as Bmp2 or Bmp4, in mice results in embryonic lethality due to multiple defects of
germ layer formation and patterning, and Bmp7 and Bmp11 knockout mice die shortly after birth
due to multiple defects in organ formation 25.

Secretion:
BMPs are synthesized as large (400-500 aa) precursors containing an N-terminal signal
peptide directing secretion, a prodomain for proper folding, and a C-terminal mature peptide.
These precursors are proteolytically cleaved by serine endoproteases to form active BMP ligands
(50-100 aa) containing seven cysteine intramolecular disulfide bonds (cysteine knots). These
bonds are essential for dimerization of BMP monomers to form biologically active homo- or

5

heterodimers (except BMP3, GDF9, and BMP15, which lack the seventh cysteine bond).
Secretion of BMPs into the extracellular space can occur either in matrix vesicles or in
association with their own ECM fibrils 17.

The Role of BMPs in Bone Formation and Skeletal Development:
The role of BMP signaling in the development of skeletal tissues and bone homeostasis
has been demonstrated in various studies

21,26,27

. The role of BMPs in patterning the skull and

regulating the skeletogenic fates of neural crest-derived mesenchyme has recently been shown,
suggesting a stage-specific regulation of the fate of chondro-osteoprogenitor cells in facial
mesenchyme 28. In vivo, expression of Bmp4 has been detected in differentiating osteoblasts 29,
whereas expression of Bmp1 and Bmp2 has been localized to mature/differentiated osteoblasts
29,30

. Overexpression of Bmp4 in osteoblasts under the control of a 2.3-kb fragment of Col1a1

promoter resulted in increased SMAD signaling and impaired bone formation at least in part due
to increased osteoclast formation 31. Transgenic mice overexpressing Noggin, a BMP antagonist
32

, under the control of a 1.7-kb fragment of rat Bglap1 promoter displayed severely impaired

bone formation and bone mineral density, and multiple long bone fractures 33. Overexpression of
another BMP antagonist, Sost, resulted in reduced bone formation in vivo and decreased
mineralization in BMSC cultures in vitro 34. In addition, both Bmp2 and Bmp4 promoters contain
several binding motifs for Runx2, a transcription factor essential for bone formation

35

.

Interestingly, Bmp2 is required for osteoblast differentiation in response to WNT signaling. In
addition, Prx1+ preosteoblasts are the target of BMP2, and it acts to induce these cells via
activation of Runx2 and Osx 36.

6

During long bone fracture healing, expression of BMP2, BMP4, and BMP7 was
upregulated, whereas expression of BMP antagonists (PRDC, SOST, SMAD7, GREM1, and
CERBERUS) was downregulated

37

, suggesting the importance of BMP signaling in the

commitment of osteoprogenitor cells to mature and produce mineralized bone matrix.
Interestingly, tissue-specific inactivation of Bmp2 in Bmp2c/c;Prx1Cre–/– mice resulted in minor
alterations in skeletal formation, delayed ossification, reduced bone mineral density, and
significantly delayed bone fracture healing 38.

In addition, multiple BMPs are expressed in bone metastases 19 and have been implicated
in the osteoclast lineage functions

39

. Furthermore, a complex regulation of BMPs during

osteogenesis by micro-RNAs, including but not limited to miRNA-133/135, 141/200a, 208/370,
and 20a, has been recently demonstrated, suggesting a more complicated regulation of
osteogenesis by BMPs than it has been considered in the past 40. In addition, BMPs mediate their
effects on osteogenesis by triggering apoptosis in the limb buds, thus allowing osteoprogenitor
cells to populate this area 41.

In vitro studies have demonstrated that continuous exposure of osteoblast cells to BMP2
stimulates their proliferation and differentiation

42,43

. Exposure of adipose-derived stem cells

(ADSCs) transfected with the Bmp2 construct to mineralization-inducing medium significantly
increased the extent of mineralization and expression of Runx2 44. Expression levels of Bmp2 and
Bmp4 were continuously increasing, as the BMSC cultures continued differentiating under
mineralization-inducing conditions 45.

7

However, not all BMPs possess the osteogenic-inducing properties. For example, BMP1
is unrelated to other BMPs, are thought to not regulate osteogenesis and acts as an enzyme to
process cleavage of procollagen fibrils and full-length NCPs 46. Nevertheless, recent case report
studies showed that inactivating mutations of Bmp1 resulted in osteogenesis imperfecta
phenotype, suggesting that BMP1 can act as a positive regulator of osteogenesis, possibly though
regulation of processing of various ECM proteins

47

. Another member of the BMP family,

BMP3, has been shown to act as a negative regulator of bone formation via upregulation of a
Sost gene and subsequent inhibition of the Wnt signaling pathway 48.

The Role of BMPs in Tooth Development and Odontoblast Differentiation:
The role of BMPs during tooth development has been well documented

20

. BMPs have

been implicated in the regulation of tooth number, size, morphology, and differentiation

49-51

.

Expression of BMPs has been detected during all stages of tooth development. In the dental
epithelium, expression of Bmp2, Bmp4, and Bmp7 has been detected as early as E10-12,
suggesting that these BMPs can function as mediators of the odontogenic potential from dental
epithelium to dental mesenchyme. In the dental mesenchyme and odontoblasts, expression of
Bmp1, Bmp2, Bmp3, and Bmp7 has been detected at the late bell stage (E16-19 and P1), when
predentin and dentin started to be deposited

30,52-57

. Expression of BMP4 has been localized to

the dental epithelium, dental mesenchyme, preodontoblasts, and at lower levels to odontoblasts,
suggesting that BMP4 can be important during early odontoblast differentiation

55,58

. The E17

dental papillae cultured in the presence of exogenous BMP2 resulted in increased production of

8

extracellular matrix 59. Mice overexpressing Runx2 in odontoblasts under the control of β-catenin
promoter impaired odontoblast differentiation, suggesting that BMP signaling can be important
in the regulation of odontoblast differentiation by Wnt signaling

60

. Furthermore, deletion of

Bmp2 or Bmp4 from cells expressing a 3.6-kb fragment of Col1a1 promoter reduced the rate of
dentin formation, impaired dentin architecture, and decreased expression of Dlx3, Dlx5, and Osx
transcription factors and Dmp1 and Dspp

61,62

. Tissue-specific inactivation of Bmp4 in dental

mesenchyme in Bmp4f/f;Wnt1Cre mice resulted in inhibition of SMAD1/5 signaling and
delayed/inhibited tooth development 63.

Similar to the bone literature, BMP1 has been thought to play insignificant roles during
tooth development and odontoblast differentiation. However, recent studies have demonstrated
that inactivating mutations of Bmp1 in Col1a1-Cre;Bmp1flox/flox;Tll1flox/flox mice resulted in
increased predentin thickness, thinner dentin, impaired odontoblast morphology, and decreased
expression of Dspp

30

. In addition, expression of BMP1 has been localized to odontoblast-like

cells in vitro and in the areas of reparative osteodentin formation in proximity to carious lesions
in vivo 64.

In vitro studies have shown that exposure of MD10-F2 immortalized preodontoblasts to
BMP2 significantly and rapidly (within 12 hrs) upregulated expression of Dspp via the NF-Y
signaling pathway

65

. Similarly, rapid (within 6-24 hrs) and concentration-dependent

upregulation of Dspp by BMP2 has been demonstrated in human dental pulp cells 66. In addition,
upregulation of Dspp by BMP2 in MDPC-23 cells involved activation of Dlx5 and Runx2 via
activation of SMAD1/5 signaling

67

. Continuous exposure of stem cells from exfoliated
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deciduous teeth (SHED)

68

, dental papilla cells

69

or stem cells of apical papilla (SCAP)

70

to

exogenous BMP2 significantly stimulated odontoblast differentiation. Continuous adenovirusdriven overexpression of Bmp2 71 or Bmp7 72 in human dental pulp cells significantly stimulated
odontoblast differentiation. Similarly, three-dimensional chitosan/dental pulp culture transfected
with Bmp7 displayed significantly increased mineralization and expression of markers of
odontoblast differentiation 73. Transfection of SCAP cells with Bmp2 resulted in fast (within 24
hrs) and significant expression of Dspp, Dmp1, and Alp, and the extent of mineralization

74

.

Exposure of integrin α7+ mesenchymal stem cells to BMP4 during the differentiation phase of in
vitro growth resulted in markedly stimulated odontoblast differentiation

75

. Overexpression of

miR-135a, an inhibitor of BMP signaling, in E14 tooth germs has suppressed the expression of
BMPR-1A and BMPR-1B and led to impaired tooth formation

76

. Stimulation of odontoblast

differentiation by BMP2 occurred via upregulation of both canonical (SMAD1/5/8) and noncanonical (MAPK) signaling pathways, including Erk1/2 77,78, p38 79,80 and JNK 81.

Despite multiple reports on the stimulatory effects of BMPs on odontoblast
differentiation, the limitations of these studies include a lack of approach to study possible stagespecific effects of BMPs. Most, if not all, of these studies, involve exposure of target cells to
exogenous

BMP

ligands

or

Bmp2-transfected

constructs

only

during

the

differentiation/mineralization phase of in vitro growth. Another limitation of these studies
includes the fact that cells are exposed to mineralization-inducing medium with the addition of
BMPs immediately or very shortly after the establishment of the culture, thus minimizing
examination of the effects of BMPs on odontogenesis before production of the mineralized
dentin-like matrix.
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BMP Receptors (BMPRs)

Structure:
BMP receptors are transmembrane serine/threonine kinases composed of two subunits,
referred to as Types I and II receptors 21,22,82,83. These proteins are conserved in evolution 84 and
contain an extracellular ligand binding domain and an intracellular serine/threonine kinase
domain. They are classified based on the presence (type I) and absence (type II) of the glycineserine (GS)-rich region located between the transmembrane and kinase domains and preceding
the kinase domain, and a short region termed L45 loop within its kinase domain

85

. There are

four types of Type I receptors, including activin-receptor-like kinase 1 (ALK1), ALK2,
BMPR1B (also called ALK3) and BMPR-1B (also called ALK6) and three types of Type II
receptors (ActR-II, ActR-IIb, and BMPR-II)

86

. Even though both types of receptors differ

substantially in their structure, they share ~78% amino acid homology 20,87,88.

Based on a similarity in their structure and function, Type I receptors can also be
classified into BMPR-I (ALK3 and ALK6) and (ii) ALK-1 groups (ALK1 and ALK2). The third
group of Type I receptors, TβR-I (ALK4, ActR-IB, ALK5/TβR-I, and ALK7) are not activated
by BMPs. These differences lead to the differential expression of these receptors in tissues and
their ligand-binding specificity. For example, BMPR-IA and ALK2 are widely expressed in a
variety of tissues, whereas BMPR-IB and ALK1 show a much more restrictive pattern of
expression 88-90.
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Ligand-binding specificity of Type I receptors depends on specific Type II receptor that
forms heterotetramer (see details below). For example, BMP2 and BMP4 ligands bind to BMPRIA and BMPR-IB, whereas BMP6 and BMP7 bind to ALK2 and with a much lower affinity to
BMPR-IB. BMP9 and BMP10 bind to ALK1 and ALK2. BMPR-II is specific to BMP ligands,
whereas ActR-II and ActR-IIB are shared by activitins, BMPs, and myostatin. When dimerized
with BMPR-I, BMPR-II affects the binding specificity of BMP ligands to the receptors 89-91.

A monomeric BMP ligand binds to a tetramer of two Type I and II receptors. The Type II
receptor is constitutively active even in the absence of a ligand, whereas Type I receptor has
FKBP12, a molecule which is bound to the unphosphorylated Type I receptor and suppresses its
activity. Activation of Type I receptor requires ligand binding, ligand-receptor oligomerization,
and transphosphorylation of its GS-box via Type II receptor

85

. Phosphorylation of the Type I

receptor at the GS domain releases the FKBP12 inhibitor and activates Type I receptor and
activates intracellular signaling pathways 20,87.

Activation:
The activation of BMP receptors has been described in details in various review
publications
BMPR-I

91

17,21,27,89

. Binding of BMP ligands to their respective BMP receptors (in particular,

) triggers a cascade of intracellular events, including canonical (SMAD-dependent)

and non-canonical (SMAD-independent) signaling pathways. Activation of the canonical
pathway is characterized by phosphorylation of SMAD1, 5, and 8 transcription factors (also
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called receptor SMADs, or R-SMADs), which destabilizes interaction with SMAD anchor
protein Endofin and facilitates interaction of SMAD1/5/8 with SMAD4 (also called Co-SMAD)
in the cytoplasm. This complex then translocates to the nucleus to regulate transcription of target
genes. Non-canonical pathway is characterized by activation of various non-SMAD signaling
pathways, including MAPK, PI3K/Akt, and others 18,19,25,83,92.

In addition to this, recent studies have demonstrated that integrins are important for
modulation (both positive and negative) of BMP signaling

93

. Furthermore, proteoglycans can

regulate the activity of BMPs and Noggin by modulation their bioavailability in the ECM, and
this regulation has been shown to be important for osteoblast differentiation

94

. Various other

diffusible and membrane/matrix-associated proteins have BMP-binding properties 95.

The importance of BMPRs in development has been demonstrated in the literature.
Deletion of Bmpr-1a or Alk2 resulted in embryonic death due to defects in multiple organs. Mice
lacking Bmpr-1b are vital but display multiple defects in appendicular skeleton and retina,
whereas mice lacking Actr-2b die shortly after birth due to defective cardiovascular system
formation 25. In addition, mice lacking components of SMAD signaling are embryonically lethal
due to multiple defects in gastrulation or organ formation (Smad1, Smad4, Smad5, and Smad7)
or viable but display multiple defects in cardiovascular and pulmonary systems (Smad6 and
Smad8) 25.

The Role of BMPRs in Bone Formation and Skeletal Development:
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The role of BMPR signaling has been discussed in details in several review publications,
and its deregulated activity has been involved in multiple human genetic skeletal disorders 92,96.

Expression of BMPR-IA, BMPR-IB, and BMPR-II is detected at high levels in the bone
97

. Transgenic mice overexpressing a dominant negative form of Bmpr1a receptor under the

control of 2.3-kb Col1a1 promoter displayed inhibition of osteoblast SMAD signaling, reduced
skeletal formation and impaired bone mineral density in vivo and inhibition of osteoblast
differentiation in vitro

98

. Tissue-specific expression of the truncated Bmpr-1b in these mice

resulted in impaired skeletal formation, delayed ossification, and inhibition of SMAD1
expression
37

98

. During fracture healing, expression of BMPR-1A and BMPR-2 was upregulated

. Interestingly, tissue-specific deletion of Bmpr2 in Prx1-expressing osteo-chondroprogenitors

resulted in unaffected SMAD1/5/8 signaling and increased bone formation and bone mass,
suggesting that increased BMP utilization of Type II receptor occurs at the expense of activin
signaling

99

. Furthermore, deletion of Bmpr1a gene from Dmp1-expressing cells resulted in

increased proliferation of Sp7+ preosteoblasts and increased bone mass via mTORC1 signaling
100

.

In vitro studies have shown that expression of both BmprIa and Bmpr2 increased after
induction of mineralization in differentiating BMSC cultures

101

. Similarly, expression of

Bmpr1a and Bmpr1b was continuously increasing as the BMSC cultures continued
differentiating in mineralization-inducing conditions 45. Inhibition of Bmpr1b by siRNA reduced
BMP2-induced expression of markers of mineralization in osteoblast cultures

102

.

Overexpression of Noggin under the control of the 2.3-kb fragment of Col1a1 promoter
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significantly impaired both bone formation and bone resorption, suggesting that regulation of
bone mass by BMP signaling is mediated through modulation of bone remodeling 31. Inactivation
of Bmpr1a using SF3b4 expression vector resulted in reduced osteogenic differentiation of
C2C12 mouse myoblast cells

103

. Overall, these results suggest that BMPRs act as positive

regulators of bone formation.

The Role of BMPRs in Tooth Development and Odontoblast Differentiation:
Several reports have demonstrated the importance of BMPRs in tooth development.
Conditional overexpression of Noggin in K14Cre;pNog mice resulted in the loss of Bmp4 and
Msx1 expression in the dental mesenchyme, significant downregulation of p38 and ERK1/2 (but
not SMADs), and arrest in tooth development at E12.5, which was rescued by simultaneous
activation of the BMP and WNT signaling pathways

104

. Condition deletion of Smad4 in

Osr2CreSmad4 mice resulted in marked inhibition of Osx and Phex in odontoblasts and impaired
dentin formation

105

. Tissue-specific deletion of Bmpr1a in the dental epithelium in K14-Cre;

Bmpr1acl/cl mice resulted in the arrest in tooth development by E16.5. Interestingly, the same
mice also displayed impaired hair follicle development, suggesting the importance of BMPR
signaling in tissues, where epithelial-mesenchymal interactions play an essential role in their
formation

106

. At all stages of tooth development, expression of Bmpr1a in developing teeth has

been localized to dental epithelium, dental mesenchyme, and odontoblasts, suggesting that BMP
signaling plays a role at various stages of odontoblast differentiation

107

. Furthermore, tissue-

specific deletion of Bmpr1a in the dental mesenchyme of Wnt1Cre;Bmpr1a mice resulted in
significantly decreased proliferation of dental mesenchyme cells and arrest in tooth development
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at E16.5

107

. In addition, BMP4-induced expression of Msx1 in developing teeth required the

presence of SMAD1/5/8 108.

Consistent with the expression of BMP ligands in cells of odontoblast lineage, expression
of BMPR-IA has been localized to epithelial and mesenchymal components of developing teeth
109

, and expression of BMPR-IB and BMPR-II has been detected in dental mesenchyme and

odontoblasts 58,110. In vitro studies have shown that expression of Alk-2, Alk-3, Alk-5, and Bmpr2
in differentiating dental pulp cultures 111. Taken together, these observations suggest that BMPRs
may play an important role during tooth development and odontoblast differentiation.

The Role of BMPR Signaling in Reparative Dentinogenesis:
The first report in the literature demonstrating the successful application of growth
factors for induction of reparative dentinogenesis was by Nakashima in 1990, who demonstrated
that crude fraction of BMPs extracted from the canine bone matrix and implanted into the cavity
of amputated dental pulp stimulated the formation of tubular-like tertiary dentin in partially
amputated pulps of adult canine teeth 112. Capping of amputated pulp with BMP2 for 2-3 weeks
in dogs resulted in the formation of substantial amounts of mixed tubular dentin and osteodentin
113

. The combination of inactivated and demineralized dentin matrix powder with either BMP2 or

BMP4 results in stimulation of reparative dentinogenesis in canine teeth 114. Active formation of
reparative dentin is observed in the areas of implantation of scaffolds loaded with BMP7 in
exposed pulp cavities in rats or miniature pigs 115-117. Capping of freshly exposed pulp chambers
with BMP7 and collagen powder for 6 weeks in monkeys resulted in the formation of reparative
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dentin, which was absent in control (no BMP7) group

118

. Continuous exposure of dental pulp

pellet cultures to BMP2 resulted in significant increases in expression of Dmp1, Dspp, and Phex,
markers of odontoblast differentiation. Implantation of dental pulp pellet pre-treated with BMP2
into the canine amputated pulp resulted in the formation of osteodentin 119. Increased expression
of BMP2 in regenerative dentin in vivo has been observed along with activated SMAD1/5/8
signaling 120,121.

Fibroblast Growth Factors (FGFs)

Description and classification:
FGF ligands are small polypeptides, which have been identified in both invertebrates and
vertebrates

122

. In vertebrates, 22 highly conserved members of the FGF family have been

currently identified, and they constitute one of the largest and well-studied families of
polypeptide growth factors. Most recent studies suggest that no other FGF genes could be
identified in the complete human genome sequence

123

. In humans and mice, FGFs are found

scattered throughout the genome, however, some of them (FGF3, 4, and 19, or FGF6 and 23) are
clustered. The increased number of FGF members occurred during expansion from one of few
archeo-FGF2 to eight pro-FGFs and during chromosomal translocation or duplication 122,124,125.

Vertebrate FGFs can be classified into several subfamilies based on their evolutionary,
biochemical, and functional properties. Based on the phylogenetic analysis (i.e. evolutionary
relationship), all FGFs are grouped into seven evolutionary divergent subfamilies according to
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their sequence homology and function: FGF A (FGF1 and 2), FGF B (FGF3, 7, 10, and 22), FGF
C (FGF4, 5, and 6), FGF D (FGF8, 17, and 18), FGF E (FGF9, 16, and 20), FGF F (FGF11-14)
and FGF G (FGF15, 19, 21, and 23)
identified

122,123

123,125-127

. Human FGF15 and mouse FGF19 have not been

. By the mechanisms of their action, all vertebrate FGFs can be classified into

canonical, or paracrine, FGFs (FGF1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18, and
FGF9/16/20), fibroblast homologous factors, or intracrine FGFs, (FHFs, FGF11/12/13/14), and
hormone-like, or endocrine, FGFs (hFGFs, FGF15 or 19/21/23) 128,129.

Expression of FGF ligands has been detected in virtually all tissues and organs. However,
many of them have a unique pattern of expression and stage of development (embryonic vs.
postnatal). For example, some FGFs (FGF3, 4, 8, 15, 17, and 19) are expressed only during
embryonic development, whereas others (FGF1, 2, 5-7, 9-14, 16, 18, and 20-23) are expressed
during both embryonic and postnatal development

122

. In teeth, expression of FGFs has been

detected in cells of dental epithelium, odontoblasts, and cells of the subodontoblastic layer but
not in the underlying dental papilla/pulp cells 130-137.

Specific patterns of FGF expression in certain types of tissue (for example, epithelial vs.
mesenchymal) could also be due to the interaction with FGF receptors expressed exclusively in a
specific type of the tissue. Functions of various FGFs during development and the phenotypes of
their loss in vertebrates have been discussed in details in several review papers 123,126,138,139.

Structure:
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FGFs contain a partially conserved core of 120–130 amino acids (~17-34 kDa in
vertebrates), and in humans, they share ~30-60% homology

140

laboratories revealed three-dimensional structure of FGF2

. In 1991, several independent
141-143

. These studies have

demonstrated that FGF2 is composed entirely of the β-trefoil structure that contains fourstranded β-sheets arranged in a pattern with approximate threefold internal symmetry
(resembling trigonal pyramid), and linked to each other by hydrogen bonds. Two β-strands (βstrands 10 and 11) contain several basic amino acid residues that form the primary heparinbinding site of FGF2. Other 10 β-strands are involved in interaction with FGF receptors and
nuclear translocation

122,144

. Although FGF2 contains four cysteine residues in its amino

sequence, biochemical analyses have demonstrated that they do not form intramolecular disulfide
bonds

145

. In addition, two inverse arginine-glycine-aspartate (RGD) sequences are identified

within FGF2, and they are shown to be important for FGF2-mediated cell adhesion and
proliferation 146.

Secretion:
Several review papers have summarized the current knowledge about secretion of various
FGF ligands

122,123,147,148

. Most of FGFs are typical growth factors, which are synthesized in the

cells and then released into the extracellular space to mediate their biological effects through
binding to FGF receptors on the surface of the same (autocrine) and/or neighboring (paracrine)
cells. A majority of FGFs (FGFs 3-8, 10, 15, 17-19, and 21-23) contain signal peptides within
their N-terminus, which allows them to get secreted through the endoplasmic reticulum
(ER)/Golgi and later translocate into the extracellular space, where they function as conventional
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growth factors by binding to FGFRs. Although FGF9, 16, and 20 lack the N-terminal signal
peptide, they are nevertheless secreted through the ER/Golgi pathway (due to their non-cleaved
N-terminal hydrophobic sequence). In contrast, LMW FGF2 (as well as FGF1 and FHFs) does
not have signal peptides, and is not secreted. Nevertheless, FGF2 mediates its signaling through
binding to the transmembrane FGF receptors, suggesting that FGF2 should be translocated to the
extracellular space. For a long time, it has been considered that FGF2 is stored in the cytosol and
can be released from the damaged cells. However, more recent studies have demonstrated that
FGF2 can also be released from intact cells by unconventional ER/Golgi-independent
mechanisms. Possible mechanisms of FGF2 secretion into the extracellular space have been
discussed in details in these review papers 149,150.

The Role of FGFs in Bone Formation and Skeletal Development:
The important roles of FGF ligands have been well documented in the literature

151,152

.

Global knockout of Fgf2 results in a significant reduction in bone formation in vivo and in vitro,
and decreased expression of markers of mineralization (Type I collagen, Osteocalcin) in cultured
BMSCs in vitro
osteoprogenitors

153-155

153

. These decreases are in part due to the decreased number of

. In addition, Fgf2–/– mice display significantly impaired anabolic effects of

PTH on osteoblast proliferation, differentiation and apoptosis 156,157. BMSCs isolated from Fgf2–
/–

mice have a substantially decreased capacity to form mineralized nodules in vitro, and these

decreases are completely reversed by exogenous FGF2 158.

Transgenic mice constitutively overexpressing human Fgf2, which encodes all FGF2
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isoforms, display various skeletal alterations, including dwarfism, shortening of long bones (~2030% reduction), severe chondrodysplasia

159,160

, markedly decreased proliferation of the growth

plate chondrocytes, and increased apoptosis of chondrocytes and calvarial osteoblasts 160. Further
studies have demonstrated that these mice have significantly decreased bone formation in vivo
and mineralization in BMSC cultures in vitro 161. However, transgenic mice overexpressing Fgf2
under the control of the Col3.6 promoter (Col3.6–18-kDa FGF2-IRES-GFPsaph mice) exhibit
significantly increased bone formation in vivo

155

. BMSC cultures derived from transgenic mice

overexpressing high molecular weight (HMW) Fgf2 under the control of the 3.6-kb Col1a1
promoter (Col3.6-HMWFgf2) display accelerated tibial fracture healing in vivo

162

, increased

osteogenic differentiation during early stages of their differentiation (1 week), however display
significantly decreased osteogenic differentiation during later stages of the culture (2-3 weeks)
163

. Inhibition of FGFR signaling by SU5402 at these later time points significantly increases the

extent of mineralization and levels of expression of markers of mineralization 163.

Multiple studies have demonstrated the stimulatory effects of FGF2 on osteoblasts during
the proliferation phase of their growth (prior to induction of differentiation). Exposure of primary
osteoblast cultures to FGF2 markedly increases the extent of mineralization 164 and expression of
markers of mineralization
activity

166

164,165

. Exposure of human BMSCs to FGF2 markedly increases ALP

. Exposure of human BMSCs to FGF2 markedly increases the extent of mineralized

tissue in vitro and after their implantation on the back of the mice in vivo 167. Early and transient
(between days 1-2) exposure of MC3T3-E1 cells to FGF2 results in a slightly increased
formation of mineralized tissue 168.
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Various studies using primary BMSCs or osteoblast cell lines have demonstrated rapid
stimulatory effects of FGF2 on the expression of markers of mineralization. Exposure of rat
ROS17/2.8 osteoblast-like cells to FGF2 induces rapid upregulation of Bsp mRNA and RUNX2
protein via activation of the Erk1/2/AP-1 signaling pathway

169

. Exposure of MC-4 osteoblast-

like cells or BMSCs to FGF2 markedly increases expression levels of Dmp1 and other osteocyteassociated markers (E11, Cx43, Phex, Sost), but decreases the expression of Alp and ALP
activity

170

. Exposure of MLO-Y4 osteocyte-like cells to FGF2 rapidly (within ~8 hrs after

exposure) stimulates expression of Dmp1 and other osteoblast/osteocyte-associated genes (Mgp,
Slc20a1)

171

. FGF2 rapidly (within ~12 hrs after exposure) increases expression of Osteocalcin

mRNA in MC-4 osteoblast-like cells 172.

These stimulatory effects of FGF2 on osteogenic differentiation are mediated, at least in
part, by the enrichment of these cultures with osteoprogenitors prior to induction of their
osteogenic differentiation. Stimulatory effects of FGF2 on the proliferation of osteoprogenitor
cells have been demonstrated in multiple studies

167,173-179

. In addition, several studies have

demonstrated anti-apoptotic effects of FGF2 on osteoprogenitor cells

180,181

, suggesting that

promoting of cell survival could also be an important mechanism of the enrichment of cultures
with osteoprogenitors.

These results correlate with the high levels of Fgf2 expression in the mesenchymal
progenitor cells of the developing mouse calvaria and low levels of expression in the calvarial
bone

182

. This suggests that FGF2 may be required for commitment of undifferentiated

progenitors towards the osteoblast lineage. However, its downregulation is required for
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maturation of osteoblasts.

FGF Receptors (FGFRs)

Description:
Paracrine FGF ligands trigger cascades of intracellular events regulating various cell
functions through interaction with transmembrane FGF receptors

148

. To date, four FGFR

transmembrane tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and FGFR4), which share a
high degree of homology, have been identified in humans and mice

148,183-185

. A fifth related

receptor, FGFR5 (also known as FGFRL1), is soluble and although it can bind FGFs, it has no
tyrosine kinase domain 186-188.

The full-length FGFRs (~800 aa), like other typical tyrosine kinase receptors, consist of
an extracellular ligand-biding domain, a single-pass transmembrane domain, and a split
intracellular tyrosine kinase domain. The extracellular region consists of a signal peptide and
three immunoglobulin-like domains (IgI, IgII, IgIII). A unique feature of FGFRs is the presence
of an acidic, serine-rich domain in the linker between IgI and IgII, termed the acid box (AB)
domain. Cysteine residues present within each Ig-like domain form an intramolecular disulfide
bond to maintain the tertiary structure of the receptor

126

. Ig-like domains play various but

distinct roles during interactions with FGF ligands. The IgI and AB domains are thought to play
a role in receptor autoinhibition, whereas the IgII and IgIII domains are necessary and sufficient
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for ligand binding and specificity 126.

The diversity of FGF receptors is enhanced by the existence of multiple alternative splice
sites that can result in the generation of numerous isoforms. Alternative mRNA splicing of the
second half of the IgIII domain of Fgfr1-Fgfr3 genes specifies the sequence of the C-terminus of
IgIII domain, resulting in either the IIIb or the IIIc isoform of the FGFR with different ligandreceptor binding specificity. In contrast, no alternative mRNA splicing of Fgfr4 gene has been
demonstrated

126

, however, two Fgfr4 isoforms resulted from alternative splicing of intron 17

have been described

189

. Thus, in vertebrates, seven FGFR proteins (FGFR1IIIb, FGFR1IIIc,

FGFR2IIIb, FGFR2IIIc, FGFR3IIIb, FGFR3IIIc, and FGFR4) differing in their ligand-binding
speciﬁcity are generated from four Fgfr genes 126,185.

High affinity of FGF ligands to specific FGF receptors suggests that different splicing
isoforms of FGFRs may have a tissue-specific pattern of expression and/or developmental stagespecific functions. For example, Fgfr1 is expressed predominantly in cells and tissues of the
mesenchymal origin, whereas Fgfr2 is expressed predominantly in tissues of the ectodermal
origin

190,191

. Expression of Fgfr3 is localized to the epithelium of the neural tube during early

mouse development and later is detected in various regions of the brain and central nervous
system and at very high levels in the cartilage rudiments of developing bone

192

. Expression of

Fgfr4 is detected in the endoderm of the developing gut at E14.5 of mouse development 193.

FGF ligands produced in either epithelial or mesenchymal tissue activate receptors of the
opposite tissue specificity, thus resulting in directional epithelial-mesenchymal signaling
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126,194-

196

. For example, FGF2, 4, 5, 6, 8, 9, 17, 19, and 20 bind to the IIIc isoform with a much higher

affinity as compared to the IIIb isoform

194,197

. In contrast, FGF3, 7, 10 and 22 bind to the IIIb

isoform with a much higher affinity as compared to the IIIc isoform

194,197

. Although almost all

FGF ligands bind to epithelial or mesenchymal FGFRs with different affinities, certain ligands
(such as FGF1) bind to both IIIb and IIIc isoforms with the same affinity

126,194,197

. Although

splicing of the extracellular domain controls ligand specificity, no evidence that this affects
intracellular signaling exists 198. For a summary of FGFR isoforms binding specific FGF ligands,
please read a review by Saichaemchan et al. 199.

Activation:
Binding of FGFs to the FGFRs results in their dimerization and autophosphorylation, and
triggers a cascade of intracellular events, including recruitment of docking and signaling proteins
at the plasma membrane 139,185. Upon binding to FGF ligands, FGF receptors undergo a series of
changes leading to their activation. After binding of an FGF ligand and HSPGs, FGF receptors
undergo dimerization leading to conformational changes in their structure, activation of the
intracellular kinase domain, and subsequent phosphorylation of the tyrosine kinase domains and
intracellular C-terminus

198,200

. Interestingly, recent studies have also demonstrated that FGFRs

can form phosphorylated dimers even in the absence of FGF ligands

201

. The complexity of

interactions between FGF ligands and receptors has allowed identification of novel regulators
and the design of multiple inhibitors of FGF/FGFR signaling 199,202-204.

Interactions with heparin or heparan sulfate proteoglycans (HSPGs):
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An important feature of paracrine FGFs is the interaction between FGFs and heparin or
heparan sulfate proteoglycans (HSPGs)

205

. It has been established that heparin is required for

FGF ligands to effectively activate FGFR in cells deficient in HSPGs or unable to synthesize
them, or in cells pretreated with heparin/HSPG-degrading enzymes. The importance of HSPGs
for FGF/FGFR signaling has first been demonstrated by studies, which show that mutations of
Sgl and Sfl, genes essential for biosynthesis and modification of HSPGs, greatly decrease the
ability of FGF signaling to activate MAPK 206. These and other studies have demonstrated that a
unique feature of FGF-FGFR interactions is that FGFs are unable to activate FGFRs without the
cooperation of HSPGs

207

. The identification of heparin/HSPGs as an active and essential

component of FGF/FGFR signaling complex suggests that FGF activity and specificity can be
modulated not only at the transcriptional and translational levels, but also at the level of
“bioavailability” 144. Thus, HSPGs control a gradient of FGF distribution in the tissues and act as
co-receptors of FGF signaling 208.

The role of FGFRs in Bone Formation and Skeletal Development:
Important roles of FGFRs in skeletal formation have been revealed in various congenital
craniofacial and skeletal disorders

209

. Expression of Fgfrs has been localized to the

mesenchymal cells of limb buds and cranial sutures, hypertrophic chondrocytes, osteoblasts, and
osteocytes

210-214

, suggesting that FGFR signaling plays an important role in bone formation

215

.

This has been further demonstrated in multiple human and animal studies, where deregulated
activities of FGFRs lead to the development of various skeletal syndromes. Inactivating
mutations of Fgfr1 lead to Pfeiffer syndrome, Kallmann syndrome, and osteoglophonic dysplasia

26

216-219

. Similarly, animal models have shown that FGFR1 acts as a positive regulator of bone

formation

220-222

. Similar to those of Fgfr1, inactivating mutations of Fgfr2 lead to various

skeletal abnormalities, including Apert syndrome
syndrome

217,227

, Jackson-Weiss syndrome

226

223,224

, Crouzon syndrome

, bent bone dysplasia

228

225,226

, Pfeiffer

, and others. Animal

models have further shown that FGFR2 acts as a positive regulator of bone formation 221,229,230.

In contrast to FGFR1 and FGFR2, mutations of FGFR3 resulted only in few human
craniofacial and skeletal disorders, including hypochondria, achondroplasia, and thanatophoric
dysplasia

231

. Deletion of Fgfr3 from cells of osteoclast lineage in Fgfr-f/f;Lysozyme-Cre mice

resulted in increased skeletal mass due to impaired osteoclast-mediated bone resorption

232

. At

least in part, the negative regulation of bone mass by FGFR3 can be mediated through increased
degradation of BMPR-1a 233.

The current role of FGFR4 in craniofacial and skeletal bone formation is currently not
clear due to a limited number of studies. The expression of FGFR4 has been detected at high
levels in the periosteal and endosteal osteoblasts in vivo and within or in proximity to
mineralized nodules in vitro 214.

The Role of FGFR Signaling in Tooth Development and Odontoblast Differentiation:
The role of FGF/FGFR signaling in tooth development has been summarized by Li et al.
234

. Expression of Fgf2 during mouse embryonic development is localized to the dental

mesenchyme and dental papilla cells

133

. In the developing mouse root structures, FGF2 is
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localized to the differentiating odontoblasts

132

. Intense expression of the FGF2 protein is

observed in the layer of differentiating and mature odontoblasts, dentin matrix, and dental papilla
cells immediately below the odontoblast layer

131,136

. These results indicate that FGF2 may be

important during various stages of odontoblast differentiation, especially in early
odontoprogenitors.

Previous studies have demonstrated a specific pattern of expression of FGFRs in cells at
early and more advanced stages of their differentiation. Similar to cells of the osteoblast lineage,
expression of Fgfr1c increases from undifferentiated dental pulp cells and preodontoblasts to
postmitotic secretory/functional odontoblasts, however, Fgfr2c is expressed in dental follicle but
not in odontoblasts

135

. Expression of Fgfr3 is primarily localized to the dental papilla cells but

not to more mature cells

135

. Overall, these studies demonstrate a differential pattern of FGFR1

and FGFR2 expression during odontoblast differentiation in vivo and suggest that they act as
important regulators of intracellular signaling in undifferentiated cells and cells committed to the
odontoblast lineage.

In contrast to multiple studies on the effects of Fgf2 deletion or overexpression on bone
formation, very little information is available on dentinogenesis, as most of the studies have
examined the tissue-specific deletions of Fgf2 and/or Fgfrs only in the dental epithelium.
Conditional inactivation of Fgfr1 under the control of a Keratin 14 promoter (K14Cre;Fgfr1fl/fl mice) leads to abnormal ameloblast structure and enamel defects in both molars
and incisors by 8 weeks of age, whereas odontoblasts appear to be unaffected 235. Tissue-specific
inactivation of Fgfr2 in the epithelium results in markedly decreased levels of DMP1 and DSP
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proteins

236

. Conditional inactivation of Fgfr2IIIb in the dental epithelium using Nkx3.1-Cre

results in the defects in enamel, impaired odontoblast organization, and reduced expression
levels of Dmp1 and Dspp

236

. Injections of BMS-645737, an inhibitor of both FGFR and

VEGFR2, lead to degeneration and necrosis of odontoblasts and formation of thinner dentin in
rat incisors 237.

Transgenic mice expressing a dominant-negative chimeric FGFR2 protein (dnFGFR-HFc
mice) display a lack of tooth buds by E18.5

238

, whereas homozygous mice lacking the IIIb-

specific isoform of Fgfr2 (Fgfr2IIIb−/− mice) display an arrest in tooth development beyond the
bud stage (E13.5)
lacZ

239

. Targeted inactivation of the IIIb-specific isoform of Fgfr2 in Fgfr2IIIb–/–

mice display tooth agenesis by E16.5

240

. Specific deletion of Fgfr2 in the dental epithelium

in K14-Cre;Fgfr2fl/fl mice results in a delay in tooth formation at the bud stage, most likely due to
the decreased proliferation of dental epithelium cells 241. Similarly, targeted deletion of Fgfr2IIIb
from the mouse germline using Cre recombinase results in the arrest of tooth development at the
bud stage 239.

Overall, these results have demonstrated that FGFRs are important for tooth
development. However, the exact role of FGF/FGFR signaling in the regulation of odontoblast
differentiation during tooth development is yet to be further investigated.

The Role of FGFR Signaling in Reparative Dentinogenesis:
Both dentin matrix and dental pulp cells contain FGF2, and its large amounts can be
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released from the dental pulp fibroblasts or endothelial cells upon their injury 242-245.

Beads loaded with FGF2 led to the formation of numerous groups of polarized cells
without deposition of the mineralized matrix

246

. In other studies, the formation of the

mineralized tissue in the area of pulp exposure in response to FGF2 has been observed.
However, this mineralized tissue does not contain dentinal tubules, suggesting the formation of
osteodentin

247

. More recent studies have expanded our understanding of the role of FGF2 in

dentin regeneration. Using FGF2-carrying gelatin hydrogel microspheres and collagen sponges
as a scaffold, Kikuchi et al. demonstrated the formation of the DSP+ mineralized tissue in the
area of pulp exposure 21 days after surgery

248

. However, authors conclude that the regenerated

dentin-like tissue is a porous aggregate composed of dentin-like particles, suggesting the
formation of a tissue other than physiological tertiary dentin, which is non-porous. Using the
same model, formation of DMP1+/Nestin– osteodentin on the surface of the regenerated pulp by
FGF2 has been demonstrated, whereas no effect is observed at lower concentrations 249. Overall,
these observations suggest that a controlled release of FGF2 can induce the formation of
reparative dentin in vivo, however further studies are needed to optimize the concentrations of
FGF2, duration of exposure and scaffold materials for a more controlled release of FGF2.

Dental pulp cells isolated from different species display marked increases in proliferation
upon treatment with FGF2, suggesting that it stimulated odontoprogenitor cells 250-254. Similarly,
FGF2-soaked beads markedly increase cell proliferation of E11 dental mesenchyme ex vivo

135

.

Concentration-dependent increases in cell proliferation in response to FGF2 have also been
demonstrated 244,255.
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Rat incisor pulp cells cultured on Type I collagen-coated gel culture exhibit a pronounced
increase in the expression of Dspp 254. Continuous exposure of hTERT-immortalized human pulp
cells to FGF2 between days 0-14 stimulates their dentinogenic differentiation and increases
expression of Dmp1 and Dspp 256.

In addition, some ex vivo studies suggest that FGF2 in a combination with other growth
factors can be involved in regulation of odontoblast polarization and functional activity. The
combination of FGF2 and BMP4 potentiates FGF2-induced increases in the expression of Dspp
254

. Cultured mouse dental papillae (E17 bell stage) exposed to either FGF2 or TGFβ1 for 6 days

do not exhibit visible morphological changes or predentin formation. However, a combination of
these growth factors induces cell polarization and leads to intense secretion of extracellular
matrix, suggesting stimulation of functional differentiation of odontoblasts 257,258.

In contrast to the positive effects described above, several studies have demonstrated the
negative effects of FGF2 on dentinogenesis. Continuous exposure of dental pulp cells isolated
from various species to FGF2 increases proliferation and significantly decreases mineralization,
ALP activity, and expression of various markers of dentinogenesis, including Dspp
253,255,259

244,250-

. Interestingly, in contrast to immortalized pulp cells continuously exposed to 50 ng/ml

FGF2 and exhibited reduced dentinogenic differentiation, lower concentrations of FGF2 (1-10
ng/ml) positively regulate expression of Dmp1 and Dspp
concentration-dependent effects of FGF2 on dentinogenesis.
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256

, further raising a possibility of

Although extended exposure of differentiating human dental pulp cells to FGF2 greatly
decreases the extent of mineralization, withdrawal of FGF2 almost completely reverses this
inhibitory effect

244

. This suggests that cells continuously exposed to FGF2 do not de-

differentiate or die, but rather retain their dentinogenic potential and are capable of
differentiating into mature odontoblasts upon withdrawal of FGF2.

Mouse tooth germs (E17 bell stage) exposed to FGF2 for 4 days display marked
decreases in dentin formation and expression of Dspp and Alp, whereas Fgf2-specific antisense
oligodeoxynucleotides exert an opposite effect. Interestingly, authors note that the same
treatment of the tooth germs isolated at the earlier stage of their development (E15 cap stage)
results in some stimulatory effects on expression of Dspp and Alp. This may suggest that FGF2
stimulates dentinogenic differentiation of less mature odontoblasts and inhibits dentinogenic
differentiation of more mature odontoblasts 260.

Overall, these results suggest that FGF2 exerts both positive and negative effects on
dentinogenic differentiation of dental pulp cells. It is important to note that cells continuously
exposed to FGF2 remain capable of differentiating into mature odontoblasts, suggesting that
FGF2 prevents terminal differentiation of odontoprogenitor cells. However, studies
demonstrating stage-specific effects of FGF2 on odontoprogenitor cells have not been reported.

Interactions Between the BMPR and FGFR Signaling Pathways

Interactions between the FGF and BMP signaling pathways during skeletal development
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have been well documented

261

. In cultured chick calvarial osteoblasts, expression of Bmp2 was

markedly upregulated by FGF2 and FGF9

221

. Fgf2–/– transgenic mice displayed markedly

reduced levels of Bmp2 in neonatal calvarial osteoblasts, the decreased ability of exogenous
BMP2 to induce mineralization in osteoblast cultures in vitro
SMAD1/5/8 signaling

263

262

, and markedly reduced

, suggesting a role of endogenous FGF2 in regulating BMP2

expression. Ex vivo exposure of fetal calvarial sutures to FGF18-soaked beads resulted in
increased expression of Fgfr1, Fgfr2, accelerated osteogenesis, and increased expression of
markers of mineralization that occurred through upregulation of BMP2 264. Exposure of cultured
rat calvarial osteoblasts to FGF2 or gain-of-function mutation of Fgfr2 resulted in marked
inhibition of BMP inhibitor Noggin leading to a phenotype similar to that of human
craniosynostosis

265

. On the other hand, dominant-negative Fgfr2 had a stimulatory effect on

noggin 265 and markedly reduced the expression of Bmp2 221,265,266. Exposure of murine calvarial
organ culture to FGF2 resulted in marked increases in the expression of Bmp2 that was mediated
though Runx2 upregulation

267

. Exposure of cultured undifferentiated mesenchymal cells from

calvarial sutures with FGF2 resulted in significant increase in the expression of Bmp2

268

. In

addition, BMP2-induced expression of Runx2 and Osx in osteoblasts was inhibited by ablation of
Fgfr1, suggesting that FGF signaling is important in mediating stimulatory effects of BMPs on
its downstream targets

269

. Implantation of beads loaded with FGF18 into the coronal sutures

stimulated osteogenesis and markedly increased expression of Bmp2, and noggin reversed these
effects

264

FGF2 antagonized retinoic acid-mediated upregulation of Bmpr-1b

270

, and

constitutive activation of Bmpr-1b restored FGF2-mediated inhibition of mineralization 271.

Similarly, several knockout studies have demonstrated the ability of the BMP and FGF
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signaling pathways to modulate the expression of each other and other components of the
respective signaling pathways during tooth development in vivo (for review, please see Balic and
Thesleff 2). The interplay between the FGF and BMP signaling pathways is important for proper
tooth development and morphology

51

. Both signaling pathways are necessary for activation of

Pax9 and Msx1 transcription factors, downstream targets of BMP signaling, in the presumptive
dental mesenchyme of developing teeth. Expression of Fgf3 in dental mesenchyme is not
detected in Msx1 knockout mice during very early stages of tooth development, and even though
the teeth in these mice develop normally, these data suggest that Msx1 is necessary for
expression of mesenchymal Fgf3

272

. Overall, these data suggest that both the BMP and FGF

signaling pathways are essential for reciprocal interactions between the epithelium and
mesenchyme during early tooth development.

Exposure of murine dental pulp cultures to FGF2 significantly increases the expression of
Runx2 and Bmp2 during the proliferation phase of in vitro growth 273. The stimulatory effects of
FGF2 on Bmp2 expression occur within 12-24 hrs, suggesting a direct stimulatory effect

274

.

Furthermore, inhibition of BMP signaling by noggin markedly decreases or inhibits FGF2mediated increases in Dmp1 and Dspp

274

. These interactions between the FGF and BMP

signaling pathways are shown to be mediated by various intracellular mediators, including
Erk1/2 275, Runx2 262,264,267, and Foxc1 276.

A number of studies have utilized the approach of controlled and stage-specific exposure
of target cells/tissues to both FGF2 and BMP2. The rationale behind this approach is a
proliferative capacity of FGF2 and a differentiation potential of BMP2, suggesting that early
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exposure of target cells to FGF2 would increase the number of progenitors exposed to the
differentiation-inducing potential of BMP2 277. In addition, this approach has been used to induce
the differentiation potential of osteoblasts derived from ageing mice and characterized by a
decreased capacity to proliferate and produce mineralized bone-like matrix 278. Interestingly, the
expression of FGF2 (and subsequent expression of β-catenin, a downstream target of Wnt
signaling) in human bone cells significantly decreases with age, suggesting that the activity of
these pathways is important for maintaining a bone-forming capacity of osteoblast progenitor
cells

279

. This approach has created a foundation for the development of multilayer biomimetic

coatings for sequential delivery of various growth factors, including FGF2 and BMP2 280-282.

Considering important roles of BMP2 and FGF2, advances in basic science research
make these growth factors suitable various dental clinical applications 283-286 287,288.
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CHAPTER II. Specific Aims

Specific Aim #1: To Examine the Effects of Early and Limited Exposure to BMP2 on
Odontoblast and Osteoblast Differentiation.

A. Examine the effects of early and limited exposure to BMP2 on mineralization, expression
of markers of mineralization and dentinogenesis, and expression of various transgenes
(BSP-GFP, DMP1-mCherry, and DSPP-Cerulean) in primary dental pulp cultures.

Specific Aim #2: To Examine the Interplay Between the BMP and FGF Signaling Pathways
on Odontoblast Differentiation in Primary Dental Pulp Cultures.

A. Examine the effects of SU5402, a specific inhibitor of FGF/FGFR signaling, on changes
induced in dental pulp by early and limited exposure to BMP2.
B. Examine the effects of noggin, a specific inhibitor of BMP/BMPR signaling, on changes
induced in dental pulp by early and limited exposure to FGF2.
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CHAPTER III. Materials and Methods

Primary dental pulp cultures.
The coronal portions of the pulps from first and second molars were isolated from 5-7day-old hemizygous BSP-GFP, DMP1-mCherry, DSPP-Cerulean, and non-transgenic pups,
as described previously

289

. All mice were maintained in the CD1 background. After

isolation, 8.75×104 cells/cm2 were grown first in Dulbecco's modified Eagle’s medium
(DMEM), 20% fetal bovine serum (FBS), 2 mM L-glutamine, 40 U/ml penicillin, 40 µg/ml
streptomycin, and 0.1 µg/ml Fungizone (Invitrogen). Three days later, the medium was
changed to DMEM containing 5% FBS. At day 7, mineralization was induced by addition of
medium containing Minimum Essential Medium alpha (αMEM), 5% FBS, with 50 µg/ml fresh
ascorbic acid and 4 mM β-glycerophosphate. The medium was changed every other day.

Primary bone marrow stromal cell (BMSC) cultures.
BMSCs were prepared from femurs and tibiae of 5-7-day-old pups as described before
289

. Briefly, single cell suspension was prepared from flushed marrows, plated at a density of

6.5×105 cells/cm2 and grown in αMEM containing 10% FBS, 40 U/ml penicillin, and 40 µg/ml
streptomycin. Three days later, the medium was changed to the medium containing αMEM and
5% FBS. At day 7, when the cells became confluent, the medium was switched to the
mineralization-inducing medium containing αMEM, 5% FBS, with 50 µg/ml fresh ascorbic acid
and 4 mM β-glycerophosphate. The medium was changed every other day.

Treatment of primary cultures with growth factors.
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To examine the effects of BMP2 and FGF2, human recombinant BMP2 (catalog #355BM-010/CF., R&D systems, Inc., Minneapolis, MN) and low molecular weight (18 kDa) bovine
FGF2 (catalog #133-FB, R&D systems, Inc., Minneapolis, MN) were used. The growth factors
were added to the cultures with fresh culture medium every other day during either the
proliferation phase of in vitro growth (between days 3-7, referred to as early and limited
exposure) or during the differentiation/mineralization phase of in vitro growth (between days 721, referred to as late and limited exposure). For experiments involved BMP2 and FGF2, 4mM
HCl and 0.1% BSA fraction V in PBS, respectively, were used as vehicle controls.

Inhibition of signaling pathways.
The FGFR inhibitor SU5402

290,291

(catalog #sc-204308, Santa Cruz Biotechnology,

Santa Cruz, CA) was dissolved in DMSO (5 µM stock solution) and added to the cultures at
various concentrations (5, 10 and 20 µM). The BMP/BMPR inhibitor noggin

292-294

(catalog

#250-38, PeproTech, Rocky Hill, NJ) was dissolved in 0.1% BSA fraction V in PBS (50 µg/ml,
or 1.08 pM, stock solution), and added to the cultures at final concentrations of 100, 200, and
300 ng/ml (2.16, 4.32, and 6.47 pM, respectively).

Detection and quantification of mineralization in primary cultures.
Mineralization in live cultures was examined and quantified by Xylenol Orange (XO)
staining, as described previously

289

. The mean epifluorescence intensity of XO staining was

measured using a multidetection monochromator microplate reader (Safire2, Tecan, Research
Triangle Park, NC), as described previously

289

. Fluorometric measurements were performed at

570/610 nm wavelength (excitation/emission) and gain of 80. The entire area of each well was
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read at a scan density of 6×6 regions (a high sensitivity flash mode). Background fluorescence
for XO was measured using unstained dental pulp cultures at the identical time points and
subtracted from respective XO measurements.

Immunocytochemistry.
Pulp cells derived from the DSPP-Cerulean transgenic mice were treated with VH or
BMP2 and processed for immunocytochemistry, as described previously

289

. Cells were fixed

with 3.7% formaldehyde in PBS for 4 minutes at room temperature (RT), incubated with 0.5%
Triton X in PBS for 10 minutes at RT, and blocked with 3% milk for 1 hr at RT. For detection of
DSPP-Cerulean, cultures were incubated with 1:1000 dilution of anti-GFP Alexa Fluor 488
conjugated antibody (Invitrogen) in 0.3% Triton X in PBS overnight at +4°C. In these cultures,
the anti-GFP antibody binds specifically to the Cerulean fluorescent protein to enhance its
visualization.

The percentage of DSPP-Cerulean+ odontoblasts in cultures was calculated as the ratio of
cells stained with the anti-GFP antibody (DSPP-Cerulean+ odontoblasts) to the total number of
Hoechst+ cells. Approximately 20x103 Hoechst+ nuclei were counted from 20-60 different
representative areas of the culture. Negative controls included (i) primary BMSC cultures
derived from DSPP-Cerulean littermates and stained with anti-GFP antibody and (ii) primary
dental pulp cultures derived from DSPP-Cerulean littermates without the addition of anti-GFP
antibody.

For detection of phospho-SMAD1/5/8, cultures were established as described above. At
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day 3, the culture medium was switched to serum-free DMEM, and cells were incubated for 5
hrs. After that, serum-free medium was replaced with the fresh medium containing BMP2,
FGF2, or BMP4 for 1 hr. After that, the cells were incubated with 1:200 dilution of rabbit antimouse phospho-SMAD1/5/8 primary antibody (Cell Signaling, Boston, MA). All samples were
then incubated with 1:400 secondary Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen) for 1
hr at RT. The nuclei were stained with 1.0 µg/ml Hoechst 33342 dye (Molecular Probes,
Invitrogen) for 15 minutes at RT. After staining, coverslips were mounted using Dako
Fluorescent Mounting Medium (Dako North America, Inc., Carpinteria, CA) and visualized
under the microscope.

Detection and quantification of mineralization in primary cultures.
GFP expression in cell cultures at various time points was examined using Zeiss
AxioObserver Z.1 microscope equipped with the AxioCam MRc digital camera and appropriate
filters. Exposure times were adjusted for optimum imaging and kept consistent for each time
point of the culture. Panoramic images of larger areas of the cultures were obtained using a
computer-controlled motorized imaging workstation and Zeiss AxioObserver Z.1 microscope.

Epifluorescence intensity of GFP.
The mean epifluorescence intensity of BSP-GFP transgene in each well was measured as
described for XO staining. The fluorometric measurement was performed at 500/540 nm
wavelength and gain 80. Background fluorescence for GFP was measured using dental pulp
cultures from non-transgenic littermates, and these values were subtracted from respective GFP
measurements.
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Fluorometric measurements were also obtained in DSPP-Cerulean cultures stained with
the anti-GFP antibody (500/540 nm wavelength and gain 80) and Hoechst 33342 dye (343/483
nm wavelength and gain 70). Background fluorescence for GFP was measured using pulp
cultures from non-transgenic littermates stained with the anti-GFP antibody, and these values
were subtracted from respective GFP measurements.

RNA extraction and quantitative PCR (qPCR) analysis.
Total RNA was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA)
according to the manufacturer's protocol and treated with RNase-free DNase to eliminate
genomic DNA. Isolated RNA was reverse transcribed by Superscript II Reverse Transcriptase
with Oligo(dT)12–18 primers (Life Technologies, Grand Island, NY). Gene expression in the
cultures was examined by TaqMan qPCR analysis using the 2-ΔΔCT method, as described
previously

295-297

. For all reactions, 9 ng of cDNA was combined with 5 µl TaqMan Universal

PCR Master Mix (Applied Biosystems, Branchburg, NJ), 2.5 µl H2O and 0.5 µl TaqMan primers
(total 10 µl). TaqMan primers for Bsp, Dmp1, Dspp, Gapdh, and Osteocalcin were purchased
from Applied Biosystems (Table 1). We defined the acceptable range of CT values representing
gene expression to be between 10 and 35 cycles, according to manufacturer’s recommendations
(Applied Biosystems, Branchburg, NJ).

Statistical analysis.
Statistical analysis was performed by GraphPad Prism 7 software (GraphPad Software,
Inc, La Jolla, CA) using one-way ANOVA analysis with the Tukey’s multiple comparison post-

41

test or unpaired two-tailed Student t-test. In all experiments, values represent mean ± SEM of at
least three independent experiments, and a *p-value ≤ 0.05 was considered statistically
significant.
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Tables.

Table 1. Primers used for TaqMan qPCR reactions.
Gene ID
Bsp
Dmp1
Dspp
Gapdh
Osteocalcin

Assay ID
Mm01208381_g1
Mm00803831_m1
Mm00515666_m1
Mm99999915_g1
Mm03413826_mH
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CHAPTER IV. Effects of Early and Limited Exposure to BMP2 on Odontoblast and
Osteoblast Differentiation

Introduction

Bone morphogenetic proteins (BMPs) are a family of signaling molecules that belong to
the transforming growth factor β (TGFβ) superfamily of growth factors. Since their first
identification and characterization in the 1960-70s

14,15

, multiple studies have demonstrated

essential roles of BMPs in embryonic development, organogenesis, fracture healing, and
reparative processes

24

. To date, over 25 distinct members of the BMP family have been

identified in almost all tissues and organs

17,18

. BMPs mediate their effects through interaction

with highly conserved transmembrane serine/threonine kinase receptors (BMPRs), referred to as
Type I and II receptors

21,82

. BMP signaling through BMPRs is also regulated by multiple local

regulators, including integrins

93

, proteoglycans

94

, and various membrane or matrix-associated

proteins 95.

Previous studies have demonstrated important regulatory roles of BMP signaling during
skeletal development and bone formation in vivo and in vitro. Deregulated BMP signaling is
associated with multiple human genetic skeletal disorders 21,26,27,92,96. In vivo, expression of Bmp2
and Bmp4 has been localized to differentiated and differentiating osteoblasts, respectively

29

.

Similarly, expression of BMP receptors (BMPR-IA, BMPR-IB, and BMPR-II) has been detected
at high levels in the bone

97

. Overexpression of BMP antagonist noggin under the control of a
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1.7-kb fragment of the rat Bglap1 promoter has led to severe abnormalities in bone formation
and bone mineral density and multiple long bone fractures

33

. Overexpression of a dominant-

negative form of Bmpr1a receptor under the control of a 2.3-kb murine Col1a1 promoter inhibits
SMAD signaling in osteoblasts and impairs skeletal formation in vivo and osteoblast
differentiation in vitro

98

. Other in vitro studies have shown that exposure of BMSC, ADSC or

osteoblast cultures to exogenous BMPs during the differentiation phase of in vitro growth results
in increased osteoblast differentiation and formation of a mineralized bone-like matrix

42-44

.

However, some BMPs, such as BMP3, negatively affect bone formation via regulation of Wnt
signaling

48

. Taken together, these resulted suggested that a majority of BMPs play a positive

role in bone formation.

Various studies have also shown essential roles of BMP signaling in tooth development
and odontoblast differentiation

20

. In the dental mesenchyme and odontoblasts, expression of

Bmp1, Bmp2, Bmp3, and Bmp7 has been detected at a late bell stage (E16-19 and P1), when
deposition of predentin and dentin starts 30,52-57,267. Furthermore, deletion of Bmp2 or Bmp4 from
cells expressing a 3.6-kb fragment of Col1a1 promoter reduced the rate of dentin formation,
impaired dentin architecture, and decreased expression of Dlx3, Dlx5, and Osx transcription
factors and Dmp1 and Dspp

61,62

. Tissue-specific inactivation of Bmp4 in dental mesenchyme in

Bmp4f/f;Wnt1Cre mice resulted in inhibition of SMAD1/5 signaling and delayed/inhibited tooth
development

63

. Inactivating mutations of Bmp1 in Col1a1- Cre;Bmp1flox/flox;Tll1flox/flox mice

resulted in increased predentin thickness, thinner dentin, impaired odontoblast morphology, and
decreased expression of Dspp 30. In addition, exposure of dental pulp cells 66,71-73, SHED cells 68
or SCAP cells

70,74

to exogenous BMP2 or Bmp2-expressing vectors significantly stimulated
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odontoblast differentiation. Taken together, these studies suggest that BMP signaling acts as a
positive regulator of odontoblast differentiation through activation of various intracellular
signaling pathways.

Previous studies in our laboratory have demonstrated that exposure of primary dental
pulp cultures to fibroblast growth factor 2 (FGF2) during the proliferation phase of in vitro
growth (referred to as short and limited exposure) does not have significant effects on the extent
of mineralization but induces significant increases in the expression of Dmp1 and Dspp and the
number of DMP1-GFP+ and DSPP-Cerulean+ odontoblasts. Our results have also shown that the
stimulatory effects of FGF2 on odontoblast differentiation are mediated through activation of
FGFR/MEK/Erk1/2 signaling, increases in Bmp2, Runx2, and Osx

273,274

, and activation of the

BMP/BMPR signaling pathway. These observations suggest that stimulatory effects of FGF
signaling on odontoblast differentiation could be mediated through induced BMP signaling.
Therefore, the goal of the experiments outlined in this thesis was to examine the effects of early
and limited exposure of primary dental pulp cultures to BMP2 on odontoblast differentiation and
examine the possible involvement of BMP signaling in stimulatory effects of FGF2 on
odontoblast differentiation.
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Results.

Signaling pathways activated by BMPs in primary dental pulp cultures.

Previous studies in our laboratory have shown that when placed in primary culture, pulp
cells from unerupted molars proliferate rapidly and reach confluence around day 7 (proliferation
phase of in vitro growth). Following addition of the mineralization-inducing medium at day 7,
these cells undergo differentiation and give rise to an extensive amount of mineralized matrix
(differentiation phase of in vitro growth). The first sign of mineralization appears around day 10
with significant increases in the extent of mineralization thereafter. At day 21 almost the entire
culture dish is covered with a sheet of mineralized tissue 274.

Using this well-characterized culture system, we first examined signaling pathways
activated by BMP2 in primary dental pulp cultures. In these experiments, the cultures were
exposed to 50 ng/ml BMP2, 50 ng/ml BMP4 or 20 ng/ml FGF2 and processed for
immunohistochemistry using antibodies against phosphorylation of SMAD1/5/8 and MAPK
ERK1/2 proteins as described in Materials and Methods. These experiments showed that the
cultures treated with BMP2 and BMP4 displayed marked increases in the number of pSMAD+
nuclei and intensity of the GFP signal as compared to VH-treated cultures (Figure 1A). These
increases in the number of pSMAD+ nuclei and intensity of the GFP signal were similar between
BMP2 and BMP4 treated cultures. In contrast to BMP-treated cultures, FGF2-treated cultures
did not display increases in the number of pSMAD+ nuclei (Figure 1A). BMP2 or BMP4
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treatment did not exert any increases in the number of pERK1/2+ nuclei, whereas their number
appeared to be somewhat increased in FGF2-treated cultures (Figure 1B). These observations
demonstrate that in primary dental pulp cultures BMP2 regulates its effects through activation of
the canonical (SMAD-dependent) signaling pathway.

Effects of early and limited exposure to BMP2 on mineralization and expression of
markers of odontoblast differentiation in primary dental pulp cultures.

We next examined the effects of early and limited exposure of dental pulp cultures to
various concentrations of BMP2 during the proliferation phase of in vitro growth. Xylenol
Orange (XO) staining showed that at all concentrations of BMP2 did not exert significant effects
on the extent of mineralization at any time point (Figure 2A-B and Table 2).

Quantitative PCR analysis showed that BMP2 affected the expression of markers of
odontoblast differentiation in a concentration-dependent manner (Figure 2C and Table 3). At day
7 the expression of Bsp (~1.7-5.6-fold) and Dmp1 (~12.0-23.0-fold) was significantly decreased
in BMP2-treated cultures at day 7 as compared to control. On the other hand, although Dspp
expression was not detected in the control cultures at day 7, its expression was stimulated by 20
and 50 ng/ml of BMP2. Expression of Ocn was not significantly affected by BMP2 at day 7.
These changes in the expression of Bsp, Dmp1, and Dspp in BMP2-treated cultures were
detected as early as 12-36 hrs after treatment (Figure 3 and Table 4). At days 10-21 the levels of
expression of Bsp and Ocn in BMP2-treated cultures were similar to those in control cultures
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(Figure 2C and Table 3). At these time points, BMP2-treated cultures displayed decreased levels
of Dmp1 (~1.2-1.5-fold) and increased levels of Dspp (~1.4-3.2-fold) as compared to control.

In addition, we observed that expression of Runx2, a downstream target of canonical
(SMAD-dependent) BMP signaling, was significantly increased by BMP2 (up to ~2.0-fold) as
early as 36 hrs after exposure (Figure 3 and Table 4).

Effects of early and limited exposure to BMP2 on expression of transgenes in primary
dental pulp cultures.

To further examine underlying mechanisms of the effects of BMP2 on dental pulp cells,
we utilized pulp cells from a series of transgenic mice that display stage-specific activation of
fluorescent proteins during odontoblast differentiation in vivo and in vitro. DMP1-mCherry and
DSPP-Cerulean transgenes were used as markers for functional and fully differentiated
odontoblasts 274, and BSP-GFP transgene was used as a marker for osteoblasts, as its expression
has not been detected in dental pulp or odontoblasts in vivo (manuscript in preparation).

Our results demonstrated that changes in the intensity of expression of BSP-GFP and
DMP1-mCherry transgenes in BMP2-treated cultures were similar to that of respective
endogenous Bsp and Dmp1 transcripts. At day 7, the intensity of BSP-GFP transgene expression
was decreased as compared to control, followed by similar levels of intensity between BMP2treated and control cultures at later time points (Figure 4A-B and Table 5). The intensity of
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DMP1-mCherry transgene expression was decreased in BMP2-treated cultures as compared to
control at all time points (Figure 4C and Table 6). As compared to control, cultures exposed to
BMP2 did not display significant changes in the percentage of DSPP-Cerulean+ odontoblasts
(Figure 5A), however BMP2 significantly increased the intensity of DSPP-Cerulean transgene
(Figure 5B and Table 7).

Effects of late and limited exposure to BMP2 on mineralization and expression of markers
of odontoblast differentiation in primary dental pulp cultures.

We also examined the effects of late and limited exposure of pulp cultures to BMP2 on
odontoblast differentiation. In these studies, BMP2 was added to the primary dental pulp cultures
during the differentiation phase of in vitro growth between days 7-21. XO staining showed that
exposure to BMP2 resulted in slight increases in the extent of mineralization at days 10 (~1.5fold), 14, and 21 as compared to control (~1.1-fold) (Figure 6A-B and Table 8).

Quantitative PCR analysis (qPCR) showed continuous increases in the expression of
markers of mineralization and odontoblast differentiation (Bsp, Ocn, Dmp1, and Dspp) in the
control cultures between days 7-21 (Figure 6C and Table 9). BMP2-treated cultures displayed
decreased levels of Bsp (~1.2-1.6-fold) and Dmp1 (~2.4-fold) as compared to control cultures.
Expression of Ocn in BMP2-treated cultures was similar to that in control, but the expression of
Dspp, a marker of odontoblast differentiation, was increased at days 10, 14, and 21 as compared
to control (~1.6-2.4-fold). Taken together, these observations showed the exposure of primary
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dental pulp cultures to BMP during the differentiation/mineralization phase of in vitro growth
resulted in increased levels of expression of Dspp but decreased expression of Dmp1 and Bsp.

Effects of early and limited exposure to BMP2 on mineralization, expression of markers of
osteoblast differentiation and transgenes in primary bone marrow stromal cell cultures.

Our previous studies showed that primary dental pulp cultures contained progenitors
capable of giving rise to both osteoblasts and odontoblasts

298

. This makes it difficult to

distinguish the effects of BMP2 on cells of osteoblast vs. odontoblast lineages and raises the
possibility that some of the effects of BMP2 on dental pulp cultures could be due to its effects on
osteoblasts rather than on odontoblasts.

To distinguish between the effects of early and limited exposure to BMP2 on cells of
odontoblast vs. osteoblast lineages, we examined the effects of BMP2 on BMSC cultures, as they
do not contain odontoprogenitors and are used routinely to examine mineralization and
osteoblast differentiation in vitro.

Our results showed that early and limited exposure of BMSC to BMP2 resulted in no
significant changes in the extent of mineralization as compared to control (Figure 7A-B and
Table 10). BMP2-treated cultures displayed concentration-dependent decreases in the intensity
of the expression of Bsp and BSP-GFP (markers of early stages of osteoblast differentiation) and
Dmp1 and DMP1-mCherry (markers of late stages of osteoblast differentiation) in a
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concentration-dependent manner (~1.3-6.2-fold) (Figure 8A-D and Tables 11-13).

52

Involvement of FGF/FGFR signaling in changes induced by early and limited exposure of
pulp cells to BMP2.

Our results showed that although early and limited exposure of pulp cultures to BMP2
did not affect mineralization, it induced changes in the expression of various markers of
odontoblast and osteoblast differentiation. These changes included decreases in the expression of
Bsp and Dmp1 as well as increases in the expression of Dspp at day 7. As the next step, we
examined the roles of the FGF/FGFR signaling pathway in mediating the stimulatory effects of
BMP2 on the expression of Dspp and its inhibitory effects of Dmp1, Bsp, and Ocn by using
SU5402. In these experiments, primary pulp cultures were treated with FGF/FGFR signaling
inhibitor SU5402 in the presence or absence of 50 ng/ml BMP2 during the proliferation phase of
in vitro growth. At day 7, all cultures were grown in control mineralization-inducing medium.

Our results showed that early and limited exposure of dental pulp cultures to 5 and 10 µM
SU5402 alone did not significantly affect the extent of mineralization at any time point, whereas
20 µM SU5402 significantly decreased it at day 21 (~1.4-fold) as compared to control (Figure
9A-B and Table 14).

Quantitative PCR analysis showed that early and limited exposure of dental pulp cultures
to SU5402 resulted in markedly decreased the expression of Bsp (up to ~2.9-fold), Dmp1 (up to
~8.5-fold), and Ocn (up to ~3.8-fold) (Figure 9C and Table 15) at day 7. On the other hand, there
were no significant changes in the levels of expression of Bsp and Dmp1 between days 10-21 in
treated cultures as compared to control. Despite the withdrawal of SU5402, there were marked
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decreases in the levels of expression of Ocn (up to ~3.8-fold) and Dspp (up to ~6.4-fold) at days
14 and 21 in treated cultures as compared to control (Figure 9C and Table 15). Effects of
SU5402 on the intensity of expression of BSP-GFP and DMP1-mCherry transgenes were similar
to those on respective endogenous transcripts (Figure 10A-C and Tables 16 and 17).

Cultures exposed to SU5402 and 50 ng/ml of BMP2 showed no significant effects on the
extent of mineralization as compared to BMP2 alone (Figure 11A-B and Table 18). Quantitative
PCR analysis showed that prior to induction of mineralization, the combination of SU5402 and
BMP2 did not reverse the decreases in the expression of Bsp, Dmp1, and Ocn but was able to
reverse the stimulatory effects of BMP2 on Dspp (Figure 11C and Table 19). Similar effects of
the combination of SU5402 and BMP2 were observed on expression of BSP-GFP and DMP1mCherry transgenes (Figure 12A-C and Tables 20 and 21). These observations together suggest
roles of FGF/FGFR signaling in mediating the stimulatory effects of BMP2 on Dspp. However,
the BMP2-induced decreases in the levels of expression of other markers of mineralization were
not mediated through FGF/FGFR signaling.

Involvement of BMP/BMPR signaling in changes induced by early and limited exposure of
pulp cells to FGF2.

Results outlined above have suggested that the interplay between BMP and FGF
signaling pathways can be important in regulation of BMP2-induced increases in Dspp
expression. To further examine the role of this interplay in pulp cultures, we exposed them to

54

various concentrations of the BMP/BMPR signaling inhibitor noggin between days 3-7.

Xylenol Orange staining demonstrated that noggin decreased the extent of mineralization
at day 10 (up to ~2-fold), but not at days 14 and 21 as compared to control (Figure 12A-B and
Table 22). Quantitative PCR analysis demonstrated that prior to induction of mineralization,
noggin significantly decreased the expression of Bsp, Dmp1, and Ocn in a concentrationdependent manner (up to ~3.5-fold), whereas no Dspp expression was observed in any cultures
(Figure 13C and Table 23). After induction of mineralization, noggin decreased the expression of
Dspp (up to ~3.3-fold at day 10) and Ocn (up to ~2.6-fold at day 21), whereas the expression of
Bsp and Dmp1 remained similar to that in control cultures (Figure 13C and Table 23). The
inhibitory effects of noggin on the expression of Bsp and Dmp1 prior to induction of
mineralization and the lack of effects on the expression of these genes after induction of
mineralization were reflected in the similar changes in the intensity of BSP-GFP and DMP1mCherry transgenes (Figure 14A-C and Tables 24 and 25).

Next, we examined the effects of inhibition of BMP signaling by noggin in the presence
of FGF2 during the proliferation phase of in vitro growth. In the presence of FGF2, noggin did
not exert significant effects on the extent of mineralization, however, 300-ng/ml concentration
resulted in the most considerable inhibitory effect (up to 1.9-fold) (Figure 15A-B and Table 26).
Quantitative PCR analysis showed that prior to induction of mineralization FGF2 markedly
increased the expression of Bsp (~2.3-fold), Dmp1 (~215-fold), Ocn (~4.6-fold), and Dspp
(~3.64-fold) as compared to control (Figure 15C and Table 27). Addition of noggin reversed
these stimulatory effects of FGF2 to the levels comparable to control (Figure 15C and Table 27).
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After induction of mineralization, noggin significantly decreased FGF2-induced expression of
Dspp (up to ~7.6-fold at days 10-21) and Ocn (up to ~6.8-fold at days 14 and 21), whereas Bsp
and Dmp1 displayed no significant changes (Figure 15C and Table 27). Effects of noggin in the
presence of FGF2 on the expression of BSP-GFP and DMP1-mCherry transgenes were similar to
those on respective endogenous transcripts (Figure 16A-C and Tables 28 and 29).
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Discussion.

Our previous studies demonstrated that FGF2 exerted stage-specific effects on
odontoblast differentiation. FGF2 stimulated differentiation of functional odontoblasts
expressing high levels of Dmp1 from early progenitors but inhibited the terminal differentiation
of functional odontoblasts to fully differentiated odontoblasts expressing high levels of Dspp 289.
Our further studies showed that the stimulatory effects of FGF2 on the differentiation of
functional odontoblasts from early progenitors involved activation of FGFR and ERK1/2 and
increased levels of expression of Bmp2, Runx2, and Osx, which are components of BMP/BMPR
signaling

273

. The inhibitory effects of FGF2 of terminal differentiation of functional

odontoblasts into fully differentiated odontoblasts were related to reactivation of FGFR/ERK1/2
signaling and downregulation of BMP/BMPR signaling 299.

In our present study, we examined the roles of BMP/BMPR signaling in the
differentiation of early progenitors by exposing the primary dental pulp cultures to BMP2
between days 3-7 (during the proliferation phase of in vitro growth). Our observation showed
that BMP2 did not affect the extent of mineralization, decreased the levels of expression of Bsp
and Dmp1, and significantly increased the levels of Dspp. The lack of significant changes in the
number of DSPP-Cerulean+ odontoblasts in BMP2-treated cultures as compared to control
indicated that increases in Dspp were related to increased transcriptional activity of Dspp but not
to the increased number of odontoblasts. These results are consistent with previously reported
stimulatory effects of BMP signaling on the expression of Dspp in vivo
65,66,69,70,74,300

.
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30,61,62

and in vitro

Previous studies also showed that these stimulatory effects of BMP2 on odontoblast
differentiation and Dspp expression were mediated through activation of both canonical
67,77,78,120,121

and non-canonical

77,79-81

signaling pathways. These stimulatory effects were rapid

and occurred within 6-24 hrs after exposure 65-67,74.

In our study we showed that exposure of dental pulp cells to BMP2 resulted in rapid (~1
hr) activation of the canonical but not non-canonical pathway evidenced by enhanced nuclear
localization of pSMAD1/5/8 (but not pERK1/2). These observations are in agreement with
previous studies showing rapid upregulation of pSMAD1/5/8 by BMP2 in the dental pulp 78 and
odontoblast-like cells

67,301

. We also showed that the increases in the expression of Dspp by

BMP2 were observed as early as 12 hrs after exposure, suggesting a direct interaction between
the activated SMAD complex with regulatory elements of Dspp. This is in agreement with the
recent study demonstrating that the Dspp promoter contains four SMAD binding elements
(SBEs) for SMAD1/5/8 and SMAD4 proteins, explaining rapid (~12 hrs) upregulation of Dspp
in mDPC6T dental papilla cells. The same study showed that a mutation of SBEs within the
promoter markedly decreased Dspp expression 302.

We further observed that early exposure to BMP2 resulted in decreased expression of Bsp
and Dmp1 as early as 36-48 hrs after exposure, and these decreases were observed up to day 21
of the culture. Considering that Bsp and Dmp1 are expressed at early and late stages of osteoblast
differentiation, respectively, and Bsp is exclusively expressed by osteoblasts, these observations
suggest that early and limited exposure of dental pulp cells to BMP2 negatively regulates
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osteoprogenitors in the dental pulp. Thus, this reveals significant differences in the response of
odontoprogenitors and osteoprogenitors to BMP2 (stimulatory and inhibitory, respectively). In
addition, decreased expression of Dmp1 and DMP1-GFP during differentiation/mineralization
phase of in vitro growth by BMP2 could result from increased odontoblast differentiation and
decreased expression of Dmp1 and DMP1-GFP in mature odontoblasts 303.

We further explored the possible mechanisms underlying decreased expression levels of
Bsp and Dmp1 in BMP2-treated pulp cultures. Previous studies have demonstrated that BMP2
stimulates expression of Dmp1 in dental pulp

78

and SCAP cells

74

. In addition, DSP-induced

expression of Dmp1 in mDPC6T dental papilla cells was inhibited by SMAD1/5/8 siRNA

302

.

Our previous studies have shown that inhibition of BMP signaling by noggin resulted in marked
decreases in FGF2-stimulated expression of Dmp1 274. Taken together, these results suggest that
BMP2 stimulates expression of Dmp1 in odontoprogenitors.

Effects of BMP signaling on Dmp1 and Bsp expression in cells of osteoblast lineage are
conflicting and report positive 268,304, negative 99,100,305 or the absence 306 of effects.

Since the negative effects of BMP2 on Dmp1 and Bsp in our experiments were observed
within 36-48 hrs, it raises a possibility of the presence of binding elements within the promoters
of these genes regulated by SMAD proteins or SMAD-associated transcription factors, such as
RUNX2. This is in agreement with previous studies showing the presence of RUNX2 binding
sites within Dmp1 and Bsp promoters 307,308 and suggests that effects of BMP2 on Dmp1 and Bsp
could be mediated through SMAD/RUNX2 signaling.
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Thus, our experiments suggest that roles of BMP signaling in the regulation of
odontoprogenitors and osteoprogenitors can be different. In addition, this could also suggest the
differences in the phenotype of osteoprogenitor cells residing in the dental pulp versus bone or
bone marrow. Using primary BMSC cultures, we demonstrated that early and limited exposure
to BMP2 resulted in decreased expression of Bsp and Dmp1, suggesting that this treatment
prevents maturation of early osteoprogenitors.

Although maturation-suppressing effects of BMP2 on early osteoprogenitors have not been
reported in the literature, they are similar to the maturation-suppressing effects of FGF2 on
osteoprogenitors reported in our previous study 289. In addition, these effects of BMP2 and FGF2
on early osteoprogenitors are consistent with the suppressing effects on osteoprogenitors by
Runx2 reported previously. Therefore, Runx2 can be a converging point essential for reciprocal
regulation of both BMP and FGF signaling pathways. This is in agreement with previous reports
demonstrating that BMP2-induced nuclear co-localization of RUNX2 and pSMAD1/5/8 (but not
pERK1/2) is impaired in Fgf2–/– mice and is dependent on the presence of FGF2

262,263

. In

addition, FGF2-stimulated expression of Bmp2 in MC3T3-E1 osteoblast-like cells is mediated by
RUNX2, as deletion of Runx2 markedly impairs this stimulation 267.

Taken together, our results suggest that increased odontoblast differentiation of early
progenitors in BMP2-treated dental pulp cultures could be due to the increased expression of
Runx2. On the other hand, increased expression of Runx2 in dental pulp or BMSC cultures can
lead to increased formation of committed early osteoprogenitors, which express lower levels of
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Dmp1 and Bsp, markers of mature osteoblasts/osteocytes.

Our further results demonstrated that inhibition of BMP signaling by noggin decreased
FGF2-induced expression of Dspp and other markers of mineralization up to day 21 of culture
(14 days after removal of noggin and FGF2). This suggests that BMP signaling is involved in
mediating stimulatory effects of FGF2 on Dspp expression. In addition, these results indicated
that the early and limited exposure of pulp cells to noggin was sufficient to exert long-lasting
inhibitory effects on Dspp expression.

Similarly, inhibition of FGF signaling by SU5402 decreased BMP2-induced expression
of Dspp and other markers of mineralization up to day 21 of culture (14 days after removal of
SU5402 and BMP2). This suggests that FGF signaling is involved in mediating stimulatory
effects of BMP2 on Dspp expression. Similar to noggin, early and limited exposure of pulp cells
to SU5402 exerted long-lasting inhibitory effects on Dspp expression.

These results indicated that there is a reciprocal interaction between the BMP and FGF
signaling pathways in their positive regulation of Dspp expression in dental pulp cultures. In
addition, they are consistent with the previously reported results demonstrating important roles
of the BMP and FGF signaling pathways in the reciprocal regulation of their activity during
tooth development and odontoblast differentiation

2,51,272

. Similarly, interactions between the

BMP (both canonical and non-canonical) and FGF signaling pathways have been well
documented during skeletal development

221,261-271

. Taken together, these data suggest that both

the BMP and FGF signaling pathways are essential for the reciprocal interactions during early
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tooth development and odontoblast differentiation.

Exposure of murine dental pulp cultures to FGF2 significantly increased the expression
of Runx2 and Bmp2 during the proliferation phase of in vitro growth 273. The stimulatory effects
of FGF2 on Bmp2 expression occurred within 12-24 hrs, suggesting a direct stimulatory effect
274

. Furthermore, inhibition of BMP signaling by noggin markedly decreased or inhibited FGF2-

mediated increases in Dmp1 and Dspp 274.

Comparison between the effects of early and limited exposure of primary dental pulp
and bone marrow stromal cell cultures to BMP2 vs. FGF2.

Our present observations of the effects of BMP2 on odontoblast differentiation of dental
pulp cells reveal some similarities and differences as compared to those of FGF2 previously
reported by us

273,289

. Neither FGF2 nor BMP2 stimulated the formation of the mineralized

matrix as compared to control. In addition, our previous observations showed that stimulatory
effects of FGF2 involved marked and rapid (within 12-24 hrs) increases in the expression of
Dspp and Dmp1 and formation of DMP1-GFP+ functional odontoblasts. In our present studies,
exposure to BMP2 led to rapid increases in the expression of Dspp, however, we did not observe
any increases in the formation of DMP1-mCherry+ functional odontoblasts. In fact, BMP2
significantly decreased the expression of Dmp1 as compared to control. In addition, BMP2stimulated odontoblast differentiation occurred through their increased transcriptional activity,
whereas FGF2-stimulated odontoblast differentiation occurred through both increased
transcriptional activity and the increased percentage of DSPP-Cerulean+ odontoblasts.
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In BMSC cultures, early and limited exposure to FGF2 resulted in decreased expression
of Col1a1, Bsp, and Ocn at day 7, whereas expression of Dmp1 and DMP1-GFP transgene was
significantly increased. BMSC cultures exposed to BMP2 showed decreased expression of Bsp,
Dmp1 and, to a lesser extent, Ocn. This further displays similarities in the early effects of FGF2
and BMP2 on osteoprogenitor cells.

Even though the physiological basis of stimulation of dentinogenesis and inhibition of
osteogenesis in undifferentiated pulp cells/progenitors is not clear, it may be important during
reparative dentinogenesis. Reparative dentinogenesis animal studies have shown that FGF2
stimulates the formation of osteodentin, which represents bone-like tissue expressing DSP and
DMP1 but negative for Nestin

309

. The formation of the mineralized tissue in the area of pulp

exposure in response to FGF2 has been observed, however, this mineralized tissue does not
contain dentinal tubules, further suggesting formation of osteodentin

247

. Using FGF2-carrying

gelatin hydrogel microspheres and collagen sponges as a scaffold, Kikuchi et al. demonstrated
formation of the DSP+ mineralized tissue in the area of pulp exposure 21 days after surgery

248

.

The regenerated tissue, however, represented a porous aggregate composed of dentin-like
particles, whereas physiological reparative dentin is non-porous. Using the same model,
formation of DMP1+/Nestin– osteodentin on the surface of the regenerated pulp by FGF2 has
been demonstrated 249.

In contrast, exposure of undifferentiated pulp cells during reparative dentinogenesis to
BMP2 resulted in the formation of tubular dentin-like tissue called orthodentin. Crude BMP
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fraction stimulated the formation of tubular-like tertiary dentin in partially amputated pulps of
adult canine teeth
115-118

112

. Capping of amputated pulp with BMP2

113,114

, BMP4

114

or BMP7/OP-1

resulted in formation of mixed osteodentin and tubular orthodentin. These results suggest

that formation of dentin-like orthodentin by BMP2 could be due to differential regulation of
commitment of undifferentiated pulp cells to odontogenic vs. osteogenic lineages.
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Summary and conclusions.

In conclusion, our results demonstrated that early and limited exposure of dental pulp cells
to BMP2 stimulated odontoblast differentiation evidenced by increased expression of Dspp and
DSPP-Cerulean transgene. We further showed that stimulatory effects of BMP2 on Dspp
expression were mediated via reciprocal interaction with FGF/FGFR signaling. In addition, we
provided in vitro evidence that this treatment resulted in a significant decrease in the expression
of markers of osteoblast differentiation (Bsp, Dmp1, BSP-GFP, and DMP1-mCherry) in both
dental pulp and BMSC cultures. These effects were largely independent of interactions with
FGF/FGFR signaling.

These results revealed similarities and differences between the effects of early and limited
exposure of dental pulp cells to BMP2 and FGF2 with a possible explanation of the differences
between these growth factors and formation of reparative dentinogenesis in vivo. These findings
provide critical information for the development of improved treatments for vital pulp therapy
and dentin regeneration.
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Figures.

Figure 1. Effects of early and limited exposure to BMP2 on phosphorylation of SMAD1/5/8
and ERK1/2 proteins in primary dental pulp cultures.
Pulp cultures derived from non-transgenic 5-7-day-old pups were exposed to 50 ng/ml BMP2, 50
ng/ml BMP4 or 20 ng/ml FGF2 at day 3 for 60 minutes as described in the Materials and
Methods. Representative images of the same area taken under brightfield (BF, upper row),
epifluorescent light using filters for detection of pSMAD1/5/8 (Panel A, middle row) or
pERK1/2 (Panel B, middle row). Bottom rows in Panels A and B represent overlaid images of
phosphorylated proteins with Hoechst 33342 (Hoechst/pSMAD and Hoechst/pERK1/2,
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respectively). Negative control (Neg. Control) included dental pulp cells exposed to 50 ng/ml
BMP2 with the omission of primary antibody. Scale bar for images in Panel A and B is 100 and
200 µm, respectively.
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Figure 2. Effects of early and limited exposure to BMP2 on the extent of mineralization and
expression of markers of mineralization and odontoblast differentiation in primary dental
pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 10, 20 or 50
ng/ml BMP2 between days 3-7 as described in the Materials and Methods. Starting day 7 all
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cultures were grown under the mineralization-inducing culture conditions in the absence of
BMP2 for additional 14 days (until day 21 of the culture).
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row) and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Expression levels of Bsp, Osteocalcin, and Dmp1 were normalized to VH at day 7, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression levels of Dspp were
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
N.D. = not detected; VH = vehicle; Bsp = Bone sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin
matrix protein 1; Dspp = Dentin sialophosphoprotein.
Early and limited exposure to any concentration of BMP2 did not exert significant effects on the
extent of mineralization as compared to control. However, BMP2 decreased the expression of
Bsp in a concentration-dependent manner at day 7 but had no effect at later time points as
compared to control. Expression of Dmp1 was decreased in a concentration-dependent manner at
day 7 and then remained lower as compared to control in cultures exposed to 50 ng/ml BMP2 (at
days 14 and 21). There was a trend for increased expression of Ocn in BMP2-treated cultures,
which did not reach statistical significance. Expression of Dspp was significantly increased in
BMP2-treated cultures in a concentration-dependent manner at all time points as compared to
control.
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Figure 3. Effects of early and limited exposure to BMP2 on the early expression of Bsp,
Dmp1, Dspp, and Runx2 in primary dental pulp cultures.
Pulp cultures were treated with VH or 50 ng/ml BMP2 starting day 3 (0 hrs) and processed for
qPCR analysis for Bsp, Dmp1, and Dspp at various time points. Expression of Bsp, Dmp1, and
Runx2 was normalized to VH at 0 hrs, which is arbitrarily set to 1 and is indicated by the dashed
line. Expression of Dspp was normalized to the BMP2-treated culture at 96 hrs, which is
arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected; VH = vehicle; Bsp = Bone sialoprotein; Dmp1 = Dentin matrix protein 1;
Dspp = Dentin sialophosphoprotein; Runx2 = Runt-related transcription factor 2.
Early and limited exposure to BMP2 significantly decreased expression of Bsp and Dmp1 and
significantly increased expression of Runx2 as early as 36-48 hrs after exposure as compared to
control. Expression of Dspp was not detected in control cultures at any time point, whereas its
expression was detected in BMP2-treated cultures as early as 12 hrs after exposure.
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Figure 4. Effects of early and limited exposure to BMP2 on the expression of BSP-GFP and
DMP1-mCherry transgenes in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old BSP-GFP and DMP1-mCherry transgenic
mice were treated with VH or BMP2 between days 3-7 as described in Materials and Methods.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (BF, upper rows) and epifluorescent light using mCherry filter for detection of
DMP1-mCherry (mCherry, middle row) and GFPtpz filter for detection of BSP-GFP (GFP,
lower row).
B. The histograms represent epifluorescence intensity of BSP-GFP transgene at various time
points.
C. The histograms represent epifluorescence intensity of BSP-GFP and DMP1-mCherry
transgene at various time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Early and limited exposure to BMP2 slightly decreased the intensity of expression of BSP-GFP
transgene at days 7 and 10, however, these changes did not reach statistical significance. No
effect on BSP-GFP was detected in BMP2-treated cultures at later time points (days 14 and 21)
as compared to control.
Expression of DMP1-mCherry transgene was significantly decreased in BMP2-treated cultures
in a concentration-dependent manner at days 7 and 10. At day 14, only 50 ng/ml BMP2
significantly decreased expression of DMP1-mCherry. No significant differences were observed
at day 21 as compared to control.
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Figure 5. Effects of early and limited exposure to BMP2 on the percentage of DSPPCerulean+ odontoblasts in primary dental pulp cultures.
Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice were treated with VH or 50
ng/ml BMP2 between days 3-7. Cultures were processed for immunocytochemistry at days 7, 10,
14, and 21 as described in the Materials and Methods.
A. The percentage of DSPP-Cerulean+ odontoblasts was calculated as a ratio between Cerulean+
cells (visualized by anti-GFP antibody) and the total number of Hoechst+ cells. Dental pulp
cultures established from DSPP-Cerulean transgenic mice and processed for
immunocytochemistry without the addition of antibody at day 21 served as a negative control
(Neg. control, without Ab).
B. The histogram represents epifluorescence intensity of DSPP-Cerulean transgene at various
time points.
Representative images of the same area taken under brightfield (BF, upper row), epifluorescent
light using filters for GFPtpz (GFP, middle row) and overlaid Hoechst/GFP (Hoechst/GFP, lower
row) filters. Scale bar is 200 µm.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Early and limited exposure to BMP2 did not affect the percentage of DSPP-Cerulean+
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odontoblasts but increased the intensity of DSPP-Cerulean transgene as compared to control.
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Figure 6. Effects of late and limited exposure to BMP2 on the extent of mineralization and
expression of markers of mineralization and odontoblast differentiation in primary dental
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pulp cultures.
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row) and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram shows the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Expression of markers of mineralization and odontoblast differentiation in the VH (control) and
BMP2-treated cultures was analyzed at days 7, 10, 14 and 21. Expression levels of Bsp,
Osteocalcin, and Dmp1 were normalized to VH at day 7, which is arbitrarily set to 1 and is
indicated by the dashed line. Expression levels of Dspp were normalized to VH at day 10, which
is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of three independent experiments; *p ≤ 0.05 relative to control at
each time point.
N.D. = not detected; VH = Vehicle; BMP2 = Bone morphogenetic protein 2; Bsp = Bone
sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin matrix protein 1; Dspp = Dentin
sialophosphoprotein.
Late and limited exposure to BMP2 significantly increased the extent of mineralization as
compared to control at day 10 but not at days 14 and 21. This treatment decreased the expression
of Bsp (at days 14 and 21) and Dmp1 (at day 21) and had similar expression levels as compared
to control. Expression of Dspp was significantly increased in BMP2-treated cultures at all time
points as compared to control.
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Figure 7. Effects of early and limited exposure to BMP2 on the extent of mineralization in
primary BMSC cultures.
Primary BMSC cultures derived from 5-7-day-old pups were grown in the presence of VH or
BMP2 at days 3-7 as described in the Materials and Methods.
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row) and epifluorescent light using TRITC Red filter for detection of XO
staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of fluorescence of XO staining at various time points.
Results represent mean ± SEM of three independent experiments; *p ≤ 0.05 relative to control at
each time point.
N.D. = not detected; VH = vehicle; BMP2 = Bone morphogenetic protein 2.
Early and limited exposure of BMSC cultures to BMP2 resulted in no changes in the extent of
mineralization as compared to control.
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Figure 8. Effects of early and limited exposure to BMP2 on the expression of BSP-GFP and
DMP1-mCherry transgenes and expression of Bsp and Dmp1 transcripts in primary BMSC
cultures.
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row) and epifluorescent light using Topaz and TRITC Red filters for
detection of DMP1-mCherry (middle row) and BSP-GFP (lower row) transgenes. Scale bar is
200 µm.
B. The histogram represents the intensity of fluorescence of BSP-GFP transgene at various time
points.
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C. The histogram represents the intensity of fluorescence of DMP1-mCherry transgene at
various time points.
D. The histograms represent expression levels of Bsp and Dmp1 transcripts at various time
points.
Results represent mean ± SEM of three independent experiments; *p ≤ 0.05 relative to control at
each time point.
N.D. = not detected; VH = vehicle; BMP2 = Bone morphogenetic protein 2. Bsp = Bone
sialoprotein; Dmp1 = Dentin matrix protein 1.
Early and limited exposure of BMSC cultures to BMP2 resulted in decreased expression of BSPGFP transgene in a concentration-dependent manner as compared to control. BMP2 treatment
reduced expression of DMP1-mCherry transgene, but these decreases largely did not reach
statistical significance.
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Figure 9. Effects of early and limited exposure to SU5402 on the extent of mineralization
and expression of markers of mineralization and odontoblast differentiation in primary
dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 5, 10, and
20 µM SU5402 between days 3-7 as described in the Materials and Methods. Starting day 7 all
cultures were grown under the control mineralization-inducing culture conditions for additional
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14 days (until day 21 of the culture).
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row), and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Expression levels of Bsp, Osteocalcin, and Dmp1 were normalized to VH at day 7, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression levels of Dspp were
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
N.D. = not detected; VH = vehicle; Bsp = Bone sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin
matrix protein 1; Dspp = Dentin sialophosphoprotein.
Early and limited exposure to SU5402 resulted in decreased mineralization at day 21 by 20 µM
concentration as compared to control. Despite a trend for decreased mineralization in SU5402treated cultures at day 14, no statistical significance was observed.
Prior to induction of mineralization at day 7, SU5402 decreased the expression of Bsp, Ocn, and
Dmp1 in a concentration-dependent manner as compared to control. No Dspp expression was
detected under any treatment. After induction of mineralization, SU5402 significantly decreased
expression of Bsp, Dmp1, Ocn, and Dspp at various time points as compared to control.

81

Figure 10. Effects of early and limited exposure to SU5402 on the expression of BSP-GFP
and DMP1-mCherry transgenes in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old BSP-GFP and DMP1-mCherry transgenic
mice were treated with VH or SU5402 between days 3-7 as described for Figure 9.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (BF, upper rows) and epifluorescent light using the mCherry filter for detection of
DMP1-mCherry (mCherry, middle row) and GFPtpz filter for detection of BSP-GFP (GFP,
lower row).
B. The histogram represents epifluorescence intensity of BSP-GFP transgene at various time
points.
C. The histogram represents epifluorescence intensity of DMP1-mCherry transgene at various
time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Prior to induction of mineralization, SU5402 decreased expression of BSP-GFP (p ≤ 0.05) and
DMP1-mCherry (p > 0.05) as compared to control. After induction of mineralization, SU5402
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decreased the intensity of expression of BSP-GFP at day 21 and DMP1-mCherry at day 10 as
compared to control.
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Figure 11. Effects of early and limited exposure to SU5402 in the presence of BMP2 on the
extent of mineralization and expression of markers of mineralization and odontoblast
differentiation in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 5, 10, and
20 µM SU5402 in the presence of 50 ng/ml BMP2 between days 3-7 as described in the
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Materials and Methods. Starting day 7 all cultures were grown under the control mineralizationinducing culture conditions for additional 14 days (until day 21 of the culture).
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row), and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Expression levels of Bsp, Osteocalcin, and Dmp1 were normalized to VH at day 7, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression levels of Dspp were
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
N.D. = not detected; VH = Vehicle; BMP2 = Bone morphogenetic protein 2; Bsp = Bone
sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin matrix protein 1; Dspp = Dentin
sialophosphoprotein.
Early and limited exposure to BMP2 had no significant effects on the extent of mineralization as
compared to control. In the presence of BMP2, SU5402 decreased the extent of mineralization as
compared to control at day 14 and by 20 µM concentration only.
Prior to induction of mineralization at day 7, BMP2 decreased the expression of Bsp, Dmp1,
Ocn, and Dspp as compared to control. Exposure of cultures to both SU5402 and BMP2 either
did not affect BMP2-mediated decreases (for Bsp, Dmp1, and Ocn) or further enhanced them (for
Dspp). After induction of mineralization, BMP2 decreased the expression of Bsp, increased
expression of Dspp, and had no significant effects on the expression of Bsp and Ocn. Exposure
of cultures to both SU5402 and BMP2 further enhanced BMP2-mediated decreases in Bsp (at
days 14 and 21), Ocn (at day 14), Dmp1 (at days 10-21), and Dspp (at days 10-21) as compared
to control.
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Figure 12. Effects of early and limited exposure to SU5402 in the presence of BMP2 on the
extent of mineralization and expression of markers of mineralization and odontoblast
differentiation in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 5, 10, and
20 µM SU5402 as described for Figure 11.
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row), and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Prior to induction of mineralization at day 7, BMP2 significantly decreased the intensity of both
BSP-GFP and DMP1-mCherry transgenes as compared to control. After induction of
mineralization, BMP2 significantly decreased intensity of BSP-GFP and DMP1-mCherry at day
10 but not at days 14 and 21 as compared to control. Exposure of cultures to both BMP2 and
SU5402 had an inhibitory effect similar to that of BMP2 but did not further enhance it.
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Figure 13. Effects of early and limited exposure to noggin on the extent of mineralization
and expression of markers of mineralization and odontoblast differentiation in primary
dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 100, 200,
and 300 ng/ml noggin between days 3-7 as described in the Materials and Methods. Starting day
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7 all cultures were grown under the control mineralization-inducing culture conditions for
additional 14 days (until day 21 of the culture).
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row), and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Expression levels of Bsp, Osteocalcin, and Dmp1 were normalized to VH at day 7, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression levels of Dspp were
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
N.D. = not detected; VH = vehicle; Bsp = Bone sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin
matrix protein 1; Dspp = Dentin sialophosphoprotein.
Early and limited exposure to all concentrations of noggin decreased the extent of mineralization
at day 10 as compared to control. Despite a trend for decreased mineralization in noggin-treated
cultures at days 14 and 21, no statistical significance was observed.
Prior to induction of mineralization at day 7, noggin decreased the expression of Bsp, Ocn, and
Dmp1 in a concentration-dependent manner as compared to control. No Dspp expression was
detected under any treatment. After induction of mineralization, noggin significantly decreased
expression of Dspp at day 10 and expression of Ocn at day 21 as compared to control. Noggin
exerted no significant effects on expression of Bsp and Dmp1 at days 10-21 as compared to
control.
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Figure 14. Effects of early and limited exposure to noggin on the expression of BSP-GFP
and DMP1-mCherry transgenes in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old BSP-GFP and DMP1-mCherry transgenic
mice were treated with VH or noggin between days 3-7 as described for Figure 13.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (BF, upper rows) and epifluorescent light using the mCherry filter for detection of
DMP1-mCherry (mCherry, middle row) and GFPtpz filter for detection of BSP-GFP (GFP,
lower row).
B. The histogram represents epifluorescence intensity of BSP-GFP transgene at various time
points.
C. The histogram represents epifluorescence intensity of DMP1-mCherry transgene at various
time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Early and limited exposure to noggin significantly decreased the intensity of expression of BSPGFP and DMP1-mCherry transgene at day7 but not at later time points as compared to control.
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Figure 15. Effects of early and limited exposure to noggin in the presence of FGF2 on the
extent of mineralization and expression of markers of mineralization and odontoblast
differentiation in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old pups were treated with VH or 100, 200,
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and 300 ng/ml noggin in the presence of 20 ng/ml FGF2 between days 3-7 as described in the
Materials and Methods. Starting day 7 all cultures were grown under the control mineralizationinducing culture conditions for additional 14 days (until day 21 of the culture).
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (BF, upper row), and epifluorescent light using TRITC Red filter for detection of
Xylenol Orange staining (XO, lower row). Scale bar is 200 µm.
B. The histogram represents the intensity of XO staining at various time points.
C. Quantitative PCR (qPCR) analysis of expression of Bsp, Ocn, Dmp1, and Dspp.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Expression levels of Bsp, Osteocalcin, and Dmp1 were normalized to VH at day 7, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression levels of Dspp were
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
N.D. = not detected; VH = vehicle; FGF2 = Fibroblast Growth Factor 2; Bsp = Bone
sialoprotein; Ocn = Osteocalcin; Dmp1 = Dentin matrix protein 1; Dspp = Dentin
sialophosphoprotein.
Early and limited exposure to FGF2 significantly increased the extent of mineralization at day 21
as compared to control. In the presence of FGF2, noggin decreased the extent of mineralization
at day 21 and at 300 ng/ml concentration only.
Prior to induction of mineralization at day 7, FGF2 markedly increased the expression of Bsp,
Dmp1, Ocn, and Dspp as compared to control. After induction of mineralization, FGF2 increased
expression of Dspp at days 10-21 but did not have significant effects on expression of other
transcripts. In the presence of FGF2, noggin decreased expression of Bsp, Dmp1, Ocn, and Dspp
at day 7, and expression of Dspp at days 14-21 and expression of Ocn at days 14 and 21 as
compared to control.
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Figure 16. Effects of early and limited exposure to noggin in the presence of FGF2 on the
expression of BSP-GFP and DMP1-mCherry transgenes in primary dental pulp cultures.
Primary dental pulp cultures derived from 5-7-day-old BSP-GFP and DMP1-mCherry transgenic
mice were treated with VH or noggin between days 3-7 as described for Figure 11.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (BF, upper rows) and epifluorescent light using the mCherry filter for detection of
DMP1-mCherry (mCherry, middle row) and the GFPtpz filter for detection of BSP-GFP (GFP,
lower row).
B. The histogram represents epifluorescence intensity of BSP-GFP transgene at various time
points.
C. The histogram represents epifluorescence intensity of DMP1-mCherry transgene at various
time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Prior to induction of mineralization, FGF2 significantly increased the intensity of expression of
BSP-GFP and DMP1-mCherry as compared to control. Noggin decreased FGF2-induced
increases in the intensity of both transgenes to the level comparable with that in control. After
induction of mineralization, all cultures had similar levels of intensity of both transgenes.
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Table 2. Concentration-dependent effects of early and limited exposure to BMP2 on
intensity of Xylenol Orange staining in primary dental pulp cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

168.75 ± 15.28

1

14

336.20 ± 28.15

1

21

814.33 ± 26.99

1

7

N.D.

–

10

186.25 ± 10.66

~1.10

14

367.80 ± 36.24

~1.09

21

810.58 ± 57.90

~1.00

7

N.D.

–

10

170.25 ± 10.79

~1.01

14

325.00 ± 33.13

~0.97

21

812.58 ± 79.25

~1.00

7

N.D.

–

10

124.00 ± 10.55

~0.73

14

310.20 ± 26.98

~0.92

21

769.08 ± 52.27

~0.94

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each time point.
N.D. = not detected.

93

Table 3. Concentration-dependent effects of early and limited exposure to BMP2 on the
expression of markers of mineralization and odontoblast differentiation in primary dental
pulp cultures.
CT

ΔCT

-ΔΔCT

Fold change

19.88 ± 0.42
25.70 ± 0.27
30.68 ± 0.44
20.90 ± 0.61
40 ± 0.00

−
5.81 ± 0.47
10.79 ± 0.66
1.01 ± 0.60
20.11 ± 0.41

−
0
0
0
N.D.

−
1
1
1
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.91 ± 0.32
20.30 ± 0.50
21.68 ± 0.25
19.24 ± 0.17
27.55 ± 1.55

−
1.39 ± 0.52
2.77 ± 0.22
0.33 ± 0.30
8.64 ± 1.42

−
4.42 ± 0.20
8.02 ± 0.45
0.68 ± 0.47
0

−
22.01 ± 2.74
301.64 ± 94.87
1.91 ± 0.67
1

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.44 ± 0.81
18.39 ± 0.59
0.28 ± 0.22
16.72 ± 1.02
25.52 ± 1.44

−
-1.04 ± 0.42
1.30 ± 0.94
-2.70 ± 0.63
6.08 ± 0.92

−
6.86 ± 0.12
9.49 ± 0.30
3.72 ± 0.07
2.56 ± 0.51

−
117.17 ± 9.65
765.16 ± 139.55
13.30 ± 0.64
7.28 ± 2.84

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

20.25 ± 0.41
17.71 ± 0.06
20.37 ± 0.82
15.85 ± 0.61
24.62 ± 1.24

−
-2.54 ± 0.36
0.12 ± 0.70
-4.39 ± 0.89
4.38 ± 1.39

−
8.35 ± 0.13
10.66 ± 0.13
5.41 ± 0.29
4.26 ± 0.11

CT

ΔCT

-ΔΔCT

Fold change

20.40 ± 0.21
27.30 ± 0.36
36.05 ± 1.13
22.15 ± 0.55
38.46 ± 0.55

−
6.91 ± 0.56
15.65 ± 0.98
1.75 ± 0.46
18.06 ± 0.53

−
-1.09 ± 0.51
-4.86 ± 1.50
-0.73 ± 0.16
N.D.

−
0.35 ± 0.14
0.08 ± 0.03
0.61 ± 0.06
N.D.

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.80 ± 0.34
19.67 ± 0.32
22.03 ± 0.34
19.19 ± 0.19
26.81 ± 0.97

−
0.87 ± 0.55
3.23 ± 0.03
0.26 ± 0.50
8.01 ± 1.01

−
4.94 ± 0.24
7.55 ± 0.68
0.75 ± 0.29
0.64 ± 0.42

−
32.02 ± 4.76
254.47 ± 102.84
1.79 ± 0.38
1.77 ± 0.50

Gapdh

19.51 ± 0.61

−

−

−

Control

Day 7

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 21

Control

Day 10

Day 7

1
4

D

BMP2 (10 ng/ml)

BMP2-treated (10 ng/ml)
Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp
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−
330.64 ± 31.08
1644.36 ± 134.76
45.19 ± 8.54
19.44 ± 1.46

Day 14

Bsp
Dmp1
Osteocalcin
Dspp

17.98 ± 0.71
21.02 ± 0.16
16.28 ± 1.07
24.74 ± 1.57

-1.53 ± 0.42
1.51 ± 0.71
-3.22 ± 0.65
5.23 ± 1.04

7.34 ± 0.13
9.28 ± 0.08
4.24 ± 0.13
3.41 ± 0.45

164.28 ± 15.60
625.37 ± 36.68
19.19 ± 1.78
12.18 ± 3.24

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.90 ± 0.46
17.25 ± 0.02
19.56 ± 0.80
15.24 ± 0.63
24.36 ± 0.87

−
-2.62 ± 0.44
0.38 ± 069
-4.83 ± 0.78
4.05 ± 1.05

−
8.43 ± 0.09
10.40 ± 0.10
5.85 ± 0.29
4.60 ± 0.38

−
348.00 ± 22.73
1368.07 ± 98.39
61.32 ± 11.97
27.10 ± 7.78

CT

ΔCT

-ΔΔCT

Fold change

20.00 ± 0.35
27.62 ± 0.26
35.40 ± 0.11
21.69 ± 0.52
36.37 ± 0.90

−
7.62 ± 0.55
15.40 ± 0.44
1.69 ± 0.44
16.37 ± 0.90

−
-1.80 ± 0.54
-4.60 ± 0.30
-0.67 ± 0.16
N.D.

−
0.35 ± 0.14
0.04 ± 0.00
0.63 ± 0.07
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.83 ± 0.35
20.04 ± 0.62
22.57 ± 0.46
18.91 ± 0.08
26.73 ± 0.91

−
1.21 ± 0.75
3.74 ± 0.24
0.08 ± 0.38
7.90 ± 0.96

−
4.60 ± 0.49
7.06 ± 0.88
0.94 ± 0.40
0.75 ± 0.48

−
28.12 ± 7.18
210.40 ± 96.01
2.17 ± 0.66
2.01 ± 0.73

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.46 ± 0.62
18.05 ± 0.52
21.21 ± 0.30
15.82 ± 0.97
24.68 ± 1.61

−
-1.41 ± 0.51
1.75 ± 0.72
-3.63 ± 0.68
5.22 ± 1.22

−
7.22 ± 0.05
9.04 ± 0.08
4.65 ± 0.14
3.42 ± 0.28

−
149.93 ± 6.07
528.74 ± 29.72
25.62 ± 2.55
11.30 ± 1.92

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

20.10 ± 0.45
17.24 ± 0.05
19.79 ± 0.76
15.00 ± 0.50
24.01 ± 0.99

−
-2.82 ± 0.43
0.34 ± 0.61
-5.23 ± 0.71
3.65 ± 1.05

−
8.64 ± 0.18
10.45 ± 0.07
6.25 ± 0.22
4.99 ± 0.39

−
408.14 ± 53.70
1402.17 ± 71.97
79.01 ± 12.26
35.44 ± 9.11

CT

ΔCT

-ΔΔCT

Fold change

19.88 ± 0.28
28.21 ± 0.11
34.59 ± 0.18
22.04 ± 0.49
35.55 ± 0.53

−
8.33 ± 0.30
15.07 ± 0.19
2.16 ± 0.45
15.67 ± 0.66

−
-2.51 ± 0.22
-4.28 ± 4.46
-1.14 ± 0.15
N.D.

−
0.18 ± 0.02
0.05 ± 0.01
0.46 ± 0.04
N.D.

BMP2 (20 ng/ml)

Day 7

BMP2-treated (20 ng/ml)
Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 7

BMP2 (50 ng/ml)

BMP2-treated (50 ng/ml)
Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp
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Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.20 ± 0.39
20.45 ± 0.27
22.96 ± 0.64
19.13 ± 0.38
26.42 ± 1.35

−
1.25 ± 0.47
3.77 ± 0.38
-0.06 ± 0.13
7.23 ± 1.28

−
4.56 ± 0.06
7.02 ± 1.02
1.08 ± 0.72
1.42 ± 0.16

−
23.70 ± 1.07
232.92 ± 115.35
2.96 ± 1.25
2.72 ± 0.30

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.67 ± 0.57
18.29 ± 0.51
21.73 ± 0.19
15.71 ± 1.04
24.31 ± 1.63

−
-1.38 ± 0.41
2.06 ± 0.57
-3.95 ± 0.64
4.64 ± 1.25

−
7.19 ± 0.10
8.73 ± 0.10
4.97 ± 0.21
4.01 ± 0.18

−
146.64 ± 6.21
428.15 ± 32.26
32.48 ± 5.13
16.48 ± 2.20

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

20.22 ± 0.45
17.49 ± 0.17
20.26 ± 1.06
14.47 ± 0.27
23.40 ± 1.06

−
-2.72 ± 0.41
0.59 ± 0.69
-5.78 ± 0.60
2.77 ± 1.28

−
8.53 ± 0.17
10.20 ± 0.04
6.80 ± 0.23
5.87 ± 0.26

−
378.66 ± 47.27
1175.12 ± 33.56
116.59 ± 20.34
61.55 ± 10.06

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day 10.
N.D. = not detected.
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Table 4. Time-dependent effects of early and limited exposure to FGF2 on expression of
Bsp, Dmp1, Dspp, and Runx2 in primary dental pulp cultures.

CT

ΔCT

-ΔΔCT

Fold change

0

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.49 ± 0.14
33.11 ± 0.57
37.47 ± 1.65
28.22 ± 0.01
25.99 ± 0.02

−
13.62 ± 0.44
17.98 ± 1.78
8.73 ± 0.13
7.88 ± 0.86

−
0
−
0
0

−
1
N.D.
1
1

12

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.59 ± 0.27
32.18 ± 0.60
36.73 ± 0.95
25.97 ± 0.36
24.33 ± 0.02

−
12.60 ± 0.33
17.14 ± 1.22
6.38 ± 0.09
6.47 ± 0.93

−
1.03 ± 0.11
−
2.35 ± 0.22
1.41 ± 0.07

−
2.05 ± 0.15
N.D.
5.20 ± 0.77
2.66 ± 0.13

24

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.98 ± 0.40
32.17 ± 1.06
36.85 ± 0.48
26.27 ± 0.02
24.55 ± 0.14

−
12.18 ± 0.66
16.87 ± 0.88
6.29 ± 0.38
6.22 ± 0.91

−
1.44 ± 0.22
−
2.44 ± 0.25
1.66 ± 0.05

−
2.77 ± 0.41
N.D.
5.59 ± 0.95
3.16 ± 0.10

36

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.68 ± 0.29
31.82 ± 0.94
37.42 ± 0.32
25.49 ± 0.19
24.31 ± 0.03

−
12.14 ± 0.66
17.74 ± 0.03
5.81 ± 0.48
6.16 ± 0.83

−
1.48 ± 0.21
−
2.92 ± 0.35
1.72 ± 0.03

−
2.86 ± 0.42
N.D.
8.01 ± 1.87
3.29 ± 0.08

48

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.72 ± 0.23
31.55 ± 0.73
37.34 ± 0.43
24.90 ± 0.03
24.32 ± 0.07

−
11.84 ± 0.50
17.62 ± 0.20
5.19 ± 0.20
6.00 ± 0.83

−
1.79 ± 0.06
−
3.54 ± 0.07
1.88 ± 0.03

−
3.45 ± 0.15
N.D.
11.67 ± 0.56
3.68 ± 0.08

72

Control
Hours
after
treatment

Gene

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.34 ± 0.04
30.03 ± 0.72
35.67 ± 0.36
23.96 ± 0.27
24.57 ± 0.12

−
10.69 ± 0.77
16.32 ± 0.40
4.23 ± 0.23
5.98 ± 0.70

−
2.93 ± 0.33
−
4.50 ± 0.10
1.90 ± 0.16

−
8.05 ± 1.78
N.D.
22.73 ± 1.52
3.79 ± 0.43

Gapdh
Dmp1

19.95 ± 0.34
28.47 ± 0.73

−
8.52 ± 0.39

−
5.11 ± 0.05

−
34.46 ± 1.20
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16.89 ± 0.97
4.09 ± 0.26
5.97 ± 0.73

−
4.64 ± 0.13
1.91 ± 0.13

N.D.
25.09 ± 2.28
3.80 ± 0.35

CT

ΔCT

-ΔΔCT

Fold change

19.49 ± 0.14
33.11 ± 0.57
37.47 ± 1.65
28.22 ± 0.01
25.99 ± 0.02

−
13.62 ± 0.44
17.98 ± 1.78
8.73 ± 0.13
7.88 ± 0.86

−
0
−
0
0

−
1
N.D.
1
1

12

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.91 ± 0.11
32.22 ± 0.65
34.20 ± 0.27
26.64 ± 0.07
24.32 ± 0.16

−
12.31 ± 0.55
14.28 ± 0.38
6.72 ± 0.04
6.03 ± 1.20

−
1.31 ± 0.11
-2.81 ± 0.35
2.01 ± 0.09
1.85 ± 0.34

−
2.50 ± 0.19
0.15 ± 0.04
4.04 ± 0.26
3.81 ± 0.87

24

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.65 ± 0.30
32.44 ± 0.98
32.41 ± 0.17
26.48 ± 0.02
24.24 ± 0.12

−
12.79 ± 0.68
12.76 ± 0.47
6.84 ± 0.28
5.87 ± 0.72

−
0.83 ± 0.24
-1.28 ± 0.26
1.89 ± 0.15
2.01 ± 0.14

−
1.83 ± 0.30
0.43 ± 0.07
3.76 ± 0.40
4.07 ± 0.39

36

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.98 ± 0.05
33.12 ± 1.16
32.12 ± 0.57
26.42 ± 0.15
24.11 ± 0.14

−
13.14 ± 1.11
12.15 ± 0.62
6.45 ± 0.20
5.49 ± 1.05

−
0.49 ± 0.67
-0.67 ± 0.11
2.28 ± 0.07
2.39 ± 0.19

−
1.71 ± 0.70
0.63 ± 0.05
4.87 ± 0.24
5.33 ± 0.70

48

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.48 ± 0.25
33.58 ± 1.26
32.03 ± 0.58
24.47 ± 0.40
24.09 ± 0.15

−
13.10 ± 1.51
12.54 ± 0.33
6.42 ± 0.15
5.47 ± 1.00

−
0.53 ± 1.07
-1.07 ± 0.40
2.31 ± 0.02
2.41 ± 0.14

−
2.31 ± 1.28
0.52 ± 0.14
4.94 ± 0.07
5.38 ± 0.53

Gapdh
Dmp1
Dspp
Bsp
Runx2

19.94 ± 0.38
32.71 ± 0.92
31.96 ± 0.40
26.26 ± 0.03
23.94 ± 0.13

−
12.78 ± 0.54
12.02 ± 0.77
6.37 ± 0.35
5.14 ± 0.55

−
0.85 ± 0.11
-0.54 ± 0.04
2.36 ± 0.22
2.74 ± 0.31

−
1.81 ± 0.13
0.69 ± 0.02
5.26 ± 0.77
6.98 ± 1.44

Gapdh

19.83 ± 0.21

−

−

−
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36.84 ± 1.31
23.93 ± 0.08
24.41 ± 0.01
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Dspp
Bsp
Runx2

0

BMP2 (50 ng/ml)
Hours
after
Gene
treatment
Gapdh
Dmp1
Dspp
Bsp
Runx2
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96

Dmp1
Dspp
Bsp
Runx2

33.99 ± 1.04
31.31 ± 0.52
26.82 ± 0.11
23.85 ± 0.18

14.16 ± 0.83
11.48 ± 0.73
7.15 ± 0.11
5.08 ± 0.71

-0.54 ± 0.39
0
1.58 ± 0.02
2.80 ± 0.15

0.74 ± 0.19
1
3.00 ± 0.05
7.06 ± 0.73

Expression of Dmp1 was normalized to untreated sample at 0 hrs, whereas Dspp was normalized
to BMP2-treated cultures at 96 hrs.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Table 5. Concentration-dependent effects of early and limited exposure to BMP2 on
expression of BSP-GFP transgene in primary dental pulp cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

BSP-GFP

Fold change

7

271.00 ± 23.96

1

10

852.00 ± 62.44

1

14

1199.00 ± 86.31

1

21

2345.00 ± 56.40

1

7

225.00 ± 36.38

~0.83

10

800.00 ± 58.73

~0.94

14

1236.00 ± 69.72

~1.03

21

2612.00 ± 32.29

~1.07

7

176.00 ± 72.02

~0.65

10

795.00 ± 34.48

~0.93

14

1186.00 ± 64.63

~0.99

21

2526.00 ± 41.62

~1.02

7

154.00 ± 52.29

~0.57

10

796.00 ± 34.88

~0.93

14

1221.00 ± 78.59

~1.02

21

2525.00 ± 87.31

~1.03

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 6. Concentration-dependent effects of early and limited exposure to BMP2 on
expression of DMP1-mCherry transgene in primary dental pulp cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

DMP1-mCherry

Fold change

7

85.00 ± 16.57

1

10

196.00 ± 1.22

1

14

1747.00 ± 90.68

1

21

2324.00 ± 228.22

1

7

81.00 ± 12.50

~0.96

10

118.00 ± 8.59

~0.60

14

1409.00 ± 121.03

~0.81

21

2206.00 ± 300.49

~0.95

7

68.00 ± 10.52

~0.80

10

88.00 ± 11.54

~0.45

14

1240.00 ± 145.34

~0.71

21

2016.00 ± 299.17

~0.87

7

19.00 ± 11.33

~0.23

10

92.00 ± 14.63

~0.47

14

966.00 ± 122.13

~0.55

21

1793.00 ± 314.58

~0.77

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.

101

Table 7. Effects of early and limited exposure to BMP2 on epifluorescence intensity of
DSPP-Cerulean transgene in primary dental pulp cultures.
Day of the
culture

VH

BMP2
(d3-7)

Fold change

7

1582.00 ± 91.95

1986.00 ± 93.91

~1.26

10

2199.00 ± 31.41

2659.00 ± 11.34

~1.21

14

2501.00 ± 135.41

3601.00 ± 83.20

~1.44

21

3872.00 ± 68.59

5551.00 ± 172.59

~1.43

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 8. Effects of late and limited exposure to BMP2 on intensity of Xylenol Orange
staining in primary dental pulp cultures.
Day of the
culture

VH

BMP2
(d7-21)

Fold change

7

N.D.

N.D.

–

10

119.34 ± 7.86

178.00 ± 10.20

~1.49

14

574.00 ± 29.32

652.00 ± 53.62

~1.14

21

940.00 ± 30.28

1093.00 ± 57.54

~1.16

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each time point.
N.D. = not detected.
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Table 9. Effects of late and limited exposure to BMP2 on the expression of markers of
mineralization and osteoblast differentiation in primary BMSC cultures.

CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

19.05 ± 0.21
25.21 ± 0.17
32.50 ± 0.12
38.52 ± 0.47
20.56 ± 0.36

−
6.16 ± 0.11
13.45 ± 0.11
19.47 ± 0.47
1.51 ± 0.20

−
0
0
N.D.
0

−
1
1
N.D.
1

19.13 ± 0.10

−

−

−

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.20 ± 0.10
24.88 ± 0.46
27.60 ± 0.34
19.09 ± 0.06

1.07 ± 0.21
5.75 ± 0.37
8.47 ± 0.44
-0.03 ± 0.15

5.09 ± 0.21
7.69 ± 0.27
0
1.55 ± 0.04

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

18.50± 0.15
18.02 ± 0.03
23.52 ± 0.53
25.12 ± 0.37
16.86 ± 0.06

−
-0.47 ± 0.18
5.02 ± 0.38
6.62 ± 0.52
-1.63 ± 0.13

−
6.63 ± 0.27
8.42 ± 0.27
1.84 ± 0.10
3.15 ± 0.21

−
105.21 ± 20.46
363.75 ± 72.88
3.63 ± 0.27
9.21 ± 1.30

21

Control
Day of
the
culture

Gene

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

19.07 ± 0.12
17.61 ± 0.06
21.84 ± 0.26
24.87 ± 0.37
14.63 ± 0.21

−
-1.45 ± 0.10
2.77 ± 0.16
5.79 ± 0.49
-4.44 ± 0.33

−
7.61 ± 0.11
10.68 ± 0.12
2.67 ± 0.07
5.95 ± 0.19

−
198.43 ± 15.48
1660.43 ± 150.68
6.40 ± 0.36
63.74 ± 8.18

ΔCT

-ΔΔCT

Fold change

−
6.16 ± 0.11
13.45 ± 0.11
19.47 ± 0.47
1.51 ± 0.20

−
0
0
N.D.
0

−
1

−
1.89 ± 0.11
6.88 ± 0.48
7.82 ± 0.33

−
4.26 ± 0.17
6.56 ± 0.40
0.64 ± 0.12

10

7

BMP2-treated between d7-21
Day of
the
Gene
CT
culture
19.05 ± 0.21
Gapdh
25.21 ± 0.17
Bsp
32.50 ± 0.12
Dmp1
38.52 ± 0.47
Dspp
20.56 ± 0.36
Osteocalcin
Gapdh
Bsp
Dmp1
Dspp

18.36 ± 0.11
20.26 ± 0.23
25.25 ± 0.37
26.19 ± 0.45
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35.18 ± 4.72
219.59 ± 43.15
1
2.93 ± 0.09

1
N.D.
1
−
19.70 ± 2.47
105.29 ± 25.22
1.58 ± 0.13

Osteocalcin

18.48 ± 0.23

0.11 ± 0.11

1.40 ± 0.15

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

18.21 ± 0.10
18.84 ± 0.25
23.88 ± 0.43
24.12 ± 0.47
16.17 ± 0.24

−
0.63 ± 0.15
5.67 ± 0.36
5.91 ± 0.53
-2.03 ± 0.34

−
5.52 ± 0.11
7.77 ± 0.24
2.55 ± 0.08
3.54 ± 0.30

21

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

19.05 ± 0.10
18.16 ± 0.15
23.06 ± 0.33
23.57 ± 0.40
14.33 ± 0.29

−
-0.88 ± 0.14
4.01 ± 0.23
4.52 ± 0.48
-4.71 ± 0.37

−
7.04 ± 0.13
9.43 ± 0.11
3.94 ± 0.50
6.23 ± 0.23

2.68 ± 0.27
−
46.45 ± 3.79
229.43 ± 41.69
5.90 ± 0.34
12.57 ± 2.90
−
133.91 ± 11.89
699.56 ± 59.37
15.43 ± 0.54
78.27 ± 12.14

All fold changes are relative to control at day 7, except for Dspp, which is relative to VH at day
10. Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative
to control at each time point.
N.D. = not detected.
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Table 10. Concentration-dependent effects of early and limited exposure to BMP2 on
intensity of Xylenol Orange staining in primary BMSC cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

Xylenol Orange

Fold change

7

N.D.

–

10

402.00 ± 23.12

1

14

849.00 ± 47.81

1

21

1057.00 ± 38.77

1

7

N.D.

–

10

392.00 ± 15.31

~0.97

14

718.00 ± 39.57

~0.87

21

1002.00 ± 66.62

~0.95

7

N.D.

–

10

384.00 ± 13.87

~0.95

14

718.00 ± 39.57

~0.85

21

986.00 ± 67.93

~0.93

7

N.D.

–

10

327.00 ± 18.00

~0.81

14

619.00 ± 47.93

~0.73

21

968.00 ± 80.05

~0.92

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
N.D. = not detected.
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Table 11. Effects of early and limited exposure to BMP2 on the expression of markers of
mineralization and osteoblast differentiation in primary BMSC cultures.
CT

ΔCT

-ΔΔCT

Fold change

20.78 ± 0.15
19.35 ± 0.03
29.05 ± 0.85

−
-1.43 ± 0.15
8.26 ± 0.67

−
0
0

−
1
1

Day 10

Gapdh
Bsp
Dmp1

21.61 ± 0.22
28.29 ± 0.81
23.22 ± 0.23

−
-3.31 ± 0.54
1.62 ± 0.49

−
1.88 ± 0.39
6.65 ± 0.18

−
3.95 ± 1.02
101.82 ± 12.32

Day 14

Gapdh
Bsp
Dmp1

21.48 ± 0.74
17.96 ± 1.14
22.45 ± 0.28

−
-3.52 ± 0.24
0.97 ± 0.62

−
2.09 ± 0.09
7.30 ± 0.05

−
4.27 ± 0.25
157.36 ± 5.56

Day 21

Gapdh
Bsp
Dmp1

20.70 ± 0.27
16.17 ± 0.01
21.01 ± 0.93

−
-4.52 ± 0.32
0.31 ± 0.59

−
3.09 ± 0.17
7.95 ± 0.08

CT

ΔCT

-ΔΔCT

Fold change

21.04 ± 0.18
19.65 ± 0.44
30.20 ± 0.34

−
-1.38 ± 0.22
9.16 ± 0.56

−
-0.05 ± 0.07
-0.90 ± 0.10

−
0.97 ± 0.04
0.54 ± 0.04

Day 10

Gapdh
Bsp
Dmp1

21.32 ± 0.30
18.48 ± 1.20
23.81 ± 0.16

−
-2.84 ± 0.83
2.49 ± 0.52

−
1.40 ± 0.68
5.77 ± 0.15

−
3.25 ± 1.34
55.16 ± 5.64

Day 14

Gapdh
Bsp
Dmp1

19.77 ± 0.16
16.91 ± 0.27
22.64 ± 0.39

−
-2.87 ± 0.07
2.87 ± 0.19

−
1.43 ± 0.08
5.39 ± 0.86

−
2.71 ± 0.15
57.60 ± 27.90

Gapdh
Bsp
Dmp1

20.11 ± 0.32
16.32 ± 0.23
22.32 ± 0.48

−
-3.79 ± 0.17
2.22 ± 0.19

−
2.36 ± 0.02
6.05 ± 0.58

−
5.13 ± 0.15
77.39 ± 28.32

CT

ΔCT

-ΔΔCT

Fold change

20.86 ± 0.18
19.83 ± 0.45
30.39 ± 0.40

−
-1.04 ± 0.23
9.53 ± 0.62

−
-0.40 ± 0.07
-1.26 ± 0.05

−
0.76 ± 0.04
0.42 ± 0.02

Control

Day 7

Gene
Gapdh
Bsp
Dmp1

Day 21

Control

BMP2 (10 ng/ml)

Day 7

BMP2-treated (10 ng/ml)
Gene
Gapdh
Bsp
Dmp1

Day 7

BMP2 (20
ng/ml)

BMP2-treated (20 ng/ml)
Gene
Gapdh
Bsp
Dmp1

107

−
8.63 ± 1.03
247.96 ± 12.92

Day 10

Gapdh
Bsp
Dmp1

21.06 ± 0.15
18.14 ± 0.76
24.22 ± 0.11

−
-2.92 ± 0.95
3.16 ± 0.30

−
1.49 ± 0.80
5.11 ± 0.97

−
3.72 ± 1.72
51.37 ± 26.95

Day 14

Gapdh
Bsp
Dmp1

19.98 ± 0.15
16.84 ± 0.11
22.96 ± 0.09

−
-3.14 ± 0.29
2.98 ± 0.27

−
1.71 ± 0.14
5.29 ± 0.94

−
3.30 ± 0.31
56.64 ± 29.02

Day 21

Gapdh
Bsp
Dmp1

20.08 ± 0.20
16.32 ± 0.14
22.88 ± 0.10

−
-3.77 ± 0.10
2.79 ± 0.14

−
2.34 ± 0.05
5.47 ± 0.81

−
5.06 ± 0.18
59.28 ± 27.79

ΔCT

-ΔΔCT

Fold change

−
-0.60 ± 0.25
9.19 ± 0.90

−
-0.83 ± 0.10
-0.92 ± 0.23

−
0.56 ± 0.04
0.54 ± 0.09

Day 10

Gapdh
Bsp
Dmp1

20.49 ± 0.22
18.04 ± 1.10
24.77 ± 0.31

−
-2.45 ± 0.83
4.28 ± 0.04

−
1.01 ± 0.68
3.99 ± 0.71

−
2.49 ± 1.03
19.84 ± 8.45

Day 14

Gapdh
Bsp
Dmp1

20.07 ± 0.07
17.20 ± 0.38
23.50 ± 0.58

−
-2.87 ± 0.47
3.42 ± 0.66

−
1.44 ± 0.32
4.84 ± 1.33

−
2.85 ± 0.61
56.76 ± 34.63

Gapdh
Bsp
Dmp1

19.78 ± 0.09
16.43 ± 0.30
22.99 ± 0.12

−
-3.35 ± 0.19
3.21 ± 0.02

−
1.92 ± 0.35
5.06 ± 0.65

−
4.00 ± 0.92
40.34 ± 16.07

BMP2 (50 ng/ml)

Day 7

CT
21.07 ± 0.23
20.47 ± 0.53
30.26 ± 0.63

Day 21

BMP2-treated (50 ng/ml)
Gene
Gapdh
Bsp
Dmp1

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7.
N.D. = not detected.
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Table 12. Concentration-dependent effects of early and limited exposure to BMP2 on
intensity of BSP-GFP transgene in primary BMSC cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

Xylenol Orange

Fold change

7

4430.00 ± 204.78

1

10

17303.00 ± 829.56

1

14

20095.00 ± 799.77

1

21

28905.00 ± 257.47

1

7

3939.00 ± 78.79

–

10

12533.00 ± 282.08

~0.89

14

15505.00 ± 458.05

~0.72

21

26988.00 ± 331.55

~0.93

7

3331.00 ± 311.62

–

10

11206.00 ± 285.93

~0.75

14

13377.00 ± 523.14

~0.67

21

26957.00 ± 253.39

~0.93

7

2091.00 ± 111.92

–

10

10257.00 ± 646.65

~0.47

14

12190.00 ± 350.99

~0.61

21

22764.00 ± 62.60

~0.79

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 13. Concentration-dependent effects of early and limited exposure to BMP2 on
intensity of DMP1-mCherry transgene in primary BMSC cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

DMP1-mCherry

Fold change

7

134.00 ± 24.14

1

10

1282.00 ± 221.68

1

14

1541.00 ± 38.18

1

21

2258.00 ± 71.01

1

7

63.00 ± 12.97

~0.47

10

1006.00 ± 209.30

~0.79

14

1274.00 ± 19.80

~0.83

21

1985.00 ± 13.89

~0.88

7

37.00 ± 24.02

~0.28

10

1036.00 ± 229.46

~0.81

14

1333.00 ± 19.46

~0.86

21

1843.00 ± 130.84

~0.82

7

29.00 ± 19.07

~0.22

10

888.00 ± 147.70

~0.69

14

1177.00 ± 56.30

~0.76

21

1901.00 ± 20.71

~0.84

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 14. Concentration-dependent effects of early and limited exposure to SU5402 on
intensity of Xylenol Orange staining in primary dental pulp cultures.

10
20

SU5402 (µM)

5

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

187.00 ± 38.68

1

14

601.00 ± 63.36

1

21

878.00 ± 51.86

1

7

N.D.

–

10

199.00 ± 51.69

~1.06

14

527.00 ± 64.31

~0.81

21

763.00 ± 51.95

~0.87

7

N.D.

–

10

188.00 ± 41.44

~1.01

14

485.00 ± 69.88

~0.81

21

687.00 ± 51.00

~0.78

7

N.D.

–

10

149.00 ± 44.84

~0.80

14

407.00 ± 36.57

~0.75

21

620.00 ± 34.72

~0.71

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent noggin
value divided by the control value for each time point.
N.D. = not detected.
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CT

ΔCT

-ΔΔCT

Fold change

18.57 ± 0.10
26.03 ± 0.22
33.07 ± 0.40
22.80 ± 0.35
40.00 ± 0.00

−
7.44 ± 0.31
14.49 ± 0.50
4.22 ± 0.26
21.43 ± 0.10

−
0
0
0
N.D.

−
1
1
1
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.25 ± 0.13
21.13 ± 0.39
24.12 ± 0.42
20.69 ± 0.35
33.57 ± 0.83

−
2.88 ± 0.27
5.87 ± 0.29
2.44 ± 0.47
15.31 ± 0.97

−
4.56 ± 0.05
8.62 ± 0.20
1.79 ± 0.22
0

−
23.69 ± 0.78
401.96 ± 55.60
3.53 ± 0.53
1

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.74 ± 0.01
18.83 ± 0.26
23.05 ± 0.34
20.89 ± 0.34
31.45 ± 1.35

−
0.10 ± 0.27
4.32 ± 0.35
2.15 ± 0.33
12.71 ± 1.34

−
7.35 ± 0.04
10.17 ± 0.15
2.07 ± 0.07
2.60 ± 0.38

−
162.73 ± 4.73
1168.36 ± 121.10
4.21 ± 0.21
6.52 ± 1.66

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.94 ± 0.18
18.18 ± 0.13
22.51 ± 0.72
19.36 ± 0.27
30.13 ± 0.58

−
-0.77 ± 0.05
3.57 ± 0.54
0.41 ± 0.45
11.81 ± 0.76

−
8.21 ± 0.37
10.92 ± 0.04
3.81 ± 0.19
4.13 ± 0.19

−
315.11 ± 76.53
1939.58 ± 54.68
14.30 ± 1.90
17.87 ± 2.38

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

18.51 ± 0.08
27.53 ± 0.05
33.91 ± 0.49
23.60 ± 0.44
40.00 ± 0.00

−
9.02 ± 0.03
15.41 ± 0.41
5.09 ± 0.13
21.49 ± 0.08

−
-1.58 ± 0.35
-0.92 ± 0.09
-0.87 ± 0.13
N.D.

−
0.35 ± 0.08
0.53 ± 0.03
0.55 ± 0.05
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.18 ± 0.18
21.07 ± 0.35
24.53 ± 0.29
21.38 ± 0.05
34.15 ± 0.43

−
2.89 ± 0.16
6.35 ± 0.10
3.20 ± 0.14
15.97 ± 0.62

−
4.55 ± 0.15
8.14 ± 0.40
1.02 ± 0.12
-0.65 ± 0.34

−
23.65 ± 2.45
303.70 ± 79.84
2.05 ± 0.11
0.67 ± 0.15

Gapdh
Bsp
Dmp1

18.33 ± 0.10
20.12 ± 0.15
22.98 ± 0.40

−
1.80 ± 0.26
4.65 ± 0.30

−
5.64 ± 0.57
9.84 ± 0.20

−
58.01 ± 20.86
931.76 ± 127.70

SU5402 (5 µM)

Day 7

Control

Day 7

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 14

Table 15. Concentration-dependent effects of early and limited exposure to SU5402 on the
expression of markers of mineralization and odontoblast differentiation in primary dental
pulp cultures.
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21.58 ± 0.70
32.32 ± 1.33

3.25 ± 0.80
13.99 ± 1.43

0.97 ± 0.54
1.32 ± 0.47

2.24 ± 0.77
2.78 ± 0.86

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.54 ± 0.22
18.32 ± 0.02
23.05 ± 0.38
18.90 ± 0.13
31.14 ± 1.02

−
-0.22 ± 0.24
4.51 ± 0.16
0.36 ± 0.35
12.60 ± 1.25

−
7.66 ± 0.56
9.99 ± 0.34
3.86 ± 0.09
2.71 ± 0.29

−
233.69 ± 82.22
1070.23 ± 242.86
14.62 ± 0.94
6.84 ± 1.34

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.18 ± 0.43
27.52 ± 0.44
34.48 ± 0.04
24.44 ± 0.47
40.00 ± 0.00

−
8.34 ± 0.87
15.31 ± 0.39
5.26 ± 0.03
20.82 ± 0.43

−
-0.91 ± 0.56
-0.82 ± 0.11
-1.04 ± 0.22
N.D.

−
0.62 ± 0.22
0.57 ± 0.42
0.50 ± 0.08
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

17.79 ± 0.12
21.37 ± 0.84
25.01 ± 0.19
21.59 ± 0.01
33.96 ± 0.26

−
3.58 ± 0.73
7.13 ± 0.08
3.81 ± 0.12
16.17 ± 0.38

−
3.86 ± 0.41
7.27 ± 0.42
0.42 ± 0.14
-1.03 ± 1.07

−
15.73 ± 4.25
167.93 ± 46.56
1.35 ± 0.13
0.78 ± 0.43

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.37 ± 0.01
20.28 ± 0.17
23.91 ± 0.40
21.75 ± 0.59
32.71 ± 0.73

−
1.91 ± 0.18
5.54 ± 0.39
3.37 ± 0.60
14.33 ± 0.74

−
5.53 ± 0.41
8.95 ± 0.11
0.85 ± 0.35
0.98 ± 0.21

−
51.81 ± 16.38
498.15 ± 38.11
1.91 ± 0.44
2.02 ± 0.30

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.32 ± 0.24
18.31 ± 0.08
23.34 ± 0.16
19.47 ± 0.01
31.49 ± 0.88

−
-0.01 ± 0.16
5.02 ± 0.08
1.15 ± 0.23
13.17 ± 1.12

−
7.45 ± 0.48
9.47 ± 0.58
3.07 ± 0.02
2.15 ± 0.16

−
194.20 ± 59.74
827.48 ± 301.14
8.43 ± 0.11
4.48 ± 0.50

Day 7
Day 10

SU5402 (20 µM)

SU5402 (10 µM)

Day 7

Day 21

Osteocalcin
Dspp

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

18.72 ± 0.33
27.40 ± 0.86
34.34 ± 0.09
24.87 ± 0.41
40.00 ± 0.00

−
8.68 ± 1.19
15.62 ± 0.24
6.15 ± 0.08
21.28 ± 0.33

−
-1.24 ± 0.88
-1.13 ± 0.24
-1.92 ± 0.18
N.D.

−
0.59 ± 0.29
0.47 ± 0.08
0.27 ± 0.03
N.D.

Gapdh
Bsp
Dmp1
Osteocalcin

18.12 ± 0.45
21.89 ± 0.40
24.85 ± 0.43
22.56 ± 0.31

−
3.78 ± 0.85
6.74 ± 0.89
4.44 ± 0.14

−
3.55 ± 0.54
7.75 ± 0.39
-0.21 ± 0.40

−
14.47 ± 4.93
231.70 ± 59.40
0.93 ± 0.24
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Dspp

34.46 ± 0.34

16.34 ± 0.11

-1.03 ± 1.07

0.78 ± 0.43

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.71 ± 0.20
20.22 ± 1.00
24.96 ± 0.31
22.43 ± 0.57
33.21 ± 0.51

−
1.51 ± 0.30
6.26 ± 0.51
3.72 ± 0.36
14.50 ± 0.31

−
5.93 ± 0.02
8.24 ± 0.01
0.50 ± 0.10
0.81 ± 0.65

−
60.97 ± 0.68
301.39 ± 1.61
1.42 ± 0.10
2.12 ± 0.84

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.72 ± 0.21
18.93 ± 0.02
23.36 ± 0.01
20.02 ± 0.11
32.58 ± 0.99

−
-0.21 ± 0.23
4.64 ± 0.20
1.30 ± 0.10
13.85 ± 0.78

−
7.24 ± 0.09
9.85 ± 0.30
2.93 ± 0.36
1.46 ± 0.17

−
151.25 ± 9.03
964.32 ± 197.22
8.08 ± 1.92
2.80 ± 0.33

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day 10.
N.D. = not detected.
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Table 16. Concentration-dependent effects of early and limited exposure to SU5402 on
intensity of BSP-GFP transgene in primary dental pulp cultures.

10
20

SU5402 µM)

5

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

793.00 ± 7.35

1

10

982.00 ± 38.28

1

14

1343.00 ± 139.82

1

21

2736.00 ± 173.58

1

7

528.00 ± 1.19

~0.67

10

956.00 ± 91.33

~0.97

14

1123.00 ± 212.17

~0.84

21

2089.00 ± 80.63

~0.76

7

517.00 ± 32.16

~0.65

10

1045.00 ± 72.46

~1.07

14

1086.00 ± 196.56

~0.81

21

1971.00 ± 33.83

~0.72

7

477.00 ± 1.00

~0.60

10

1119.00 ± 75.26

~1.14

14

995.00 ± 157.09

~0.74

21

1798.00 ± 94.52

~0.97

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 17. Concentration-dependent effects of early and limited exposure to SU5402 on
intensity of DMP1-mCherry transgene in primary dental pulp cultures.

10
20

SU5402 µM)

5

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

93.00 ± 6.27

1

10

253.00 ± 26.47

1

14

1713.00 ± 58.30

1

21

2452.00 ± 65.48

1

7

85.00 ± 7.56

~0.91

10

173.00 ± 13.86

~0.68

14

1454.00 ± 41.12

~0.85

21

1859.00 ± 53.97

~0.76

7

79.00 ± 8.66

~0.85

10

162.00 ± 37.35

~0.64

14

1627.00 ± 77.11

~0.95

21

1916.00 ± 7.38

~0.78

7

61.00 ± 12.61

~0.65

10

169.00 ± 14.66

~0.67

14

1765.00 ± 127.42

~1.03

21

1918.00 ± 4.11

~0.80

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 18. Concentration-dependent effects of early and limited exposure to SU5402 in
combination with BMP2 on intensity of Xylenol Orange staining in primary dental pulp
cultures.

10
20

BMP2 + SU5402 (µM)

5

BMP2

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

187.00 ± 38.68

1

14

601.00 ± 63.36

1

21

878.00 ± 51.86

1

7

N.D.

–

10

179.00 ± 57.15

~0.96

14

448.00 ± 52.71

~0.74

21

1001.00 ± 72.20

~1.14

7

N.D.

–

10

178.00 ± 41.98

~0.95

14

448.00 ± 37.48

~0.74

21

975.00 ± 102.17

~1.11

7

N.D.

–

10

163.00 ± 32.90

~0.87

14

419.00 ± 47.70

~0.70

21

858.00 ± 71.10

~0.98

7

N.D.

–

10

137.00 ± 25.01

~0.73

14

312.00 ± 33.27

~0.52

21

738.00 ± 41.32

~0.84

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by control value for each time point. N.D. = not detected.
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CT

ΔCT

-ΔΔCT

Fold change

18.57 ± 0.10
26.03 ± 0.22
33.07 ± 0.40
22.80 ± 0.35
40.00 ± 0.00

−
7.44 ± 0.31
14.49 ± 0.50
4.22 ± 0.26
21.43 ± 0.10

−
0
0
0
N.D.

−
1
1
1
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.25 ± 0.13
21.13 ± 0.39
24.12 ± 0.42
20.69 ± 0.35
33.57 ± 0.83

−
2.88 ± 0.27
5.87 ± 0.29
2.44 ± 0.47
15.31 ± 0.97

−
4.56 ± 0.05
8.62 ± 0.20
1.79 ± 0.22
0

−
23.69 ± 0.78
401.96 ± 55.60
3.53 ± 0.53
1

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.74 ± 0.01
18.83 ± 0.26
23.05 ± 0.34
20.89 ± 0.34
31.45 ± 1.35

−
0.10 ± 0.27
4.32 ± 0.35
2.15 ± 0.33
12.71 ± 1.34

−
7.35 ± 0.04
10.17 ± 0.15
2.07 ± 0.07
2.60 ± 0.38

−
162.73 ± 4.73
1168.36 ± 121.10
4.21 ± 0.21
6.52 ± 1.66

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.94 ± 0.18
18.18 ± 0.13
22.51 ± 0.72
19.36 ± 0.27
30.13 ± 0.58

−
-0.77 ± 0.05
3.57 ± 0.54
0.41 ± 0.45
11.81 ± 0.76

−
8.21 ± 0.37
10.92 ± 0.04
3.81 ± 0.19
4.13 ± 0.19

−
315.11 ± 76.53
1939.58 ± 54.68
14.30 ± 1.90
17.87 ± 2.38

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

18.40 ± 0.23
27.46 ± 0.65
33.88 ± 0.02
23.59 ± 0.11
33.14 ± 1.29

−
6.06 ± 0.87
15.49 ± 0.01
5.19 ± 0.34
14.75 ± 1.06

−
-1.62 ± 0.56
-1.00 ± 0.49
-0.97 ± 0.59
0.57 ± 0.10

−
0.38 ± 0.13
0.56 ± 0.18
0.60 ± 0.22
1.49 ± 0.10

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.09 ± 0.41
21.58 ± 0.17
24.41 ± 0.20
22.05 ± 0.20
31.83 ± 1.19

−
3.48 ± 0.58
6.32 ± 0.20
3.96 ± 0.61
13.74 ± 0.79

−
3.96 ± 0.26
8.17 ± 0.30
0.26 ± 0.87
1.58 ± 0.17

−
16.05 ± 2.88
301.20 ± 60.04
1.66 ± 0.81
3.03 ± 0.35

Gapdh
Bsp
Dmp1

18.21 ± 0.23
19.08 ± 0.12
23.00 ± 0.27

−
0.87 ± 0.35
4.79 ± 0.04

−
6.57 ± 0.04
9.70 ± 0.54

−
95.10 ± 2.49
947.78 ± 332.96

BMP2 (50 ng/ml)

Day 7

Control

Day 7

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 14

Table 19. Concentration-dependent effects of early and limited exposure to SU5402 in
combination with BMP2 on expression of markers of mineralization and odontoblast
differentiation in primary dental pulp cultures.
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20.28 ± 0.59
30.72 ± 1.49

2.07 ± 0.36
12.51 ± 1.26

2.15 ± 0.10
2.80 ± 0.30

4.47 ± 0.32
7.27 ± 1.47

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.66 ± 0.28
17.98 ± 0.25
22.32 ± 0.08
18.77 ± 0.35
28.15 ± 0.71

−
-0.68 ± 0.03
3.66 ± 0.36
0.11 ± 0.08
9.49 ± 0.43

−
8.12 ± 0.29
10.83 ± 0.14
4.11 ± 0.18
5.82 ± 0.53

−
288.74 ± 56.32
1842.55 ± 175.77
17.53 ± 2.16
64.17 ± 21.40

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

18.63 ± 0.07
27.52 ± 0.66
34.36 ± 0.02
25.22 ± 0.76
35.43 ± 1.41

−
8.89 ± 0.58
15.74 ± 0.05
6.59 ± 0.83
16.80 ± 0.27

−
1.45 ± 0.27
-1.24 ± 0.55
-2.36 ± 0.57
-1.49 ± 0.52

−
0.38 ± 0.07
0.49 ± 0.17
0.23 ± 0.08
0.40 ± 0.13

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

17.76 ± 0.21
21.70 ± 0.02
25.09 ± 0.08
21.81 ± 0.56
32.39 ± 0.96

−
3.94 ± 0.23
6.32 ± 0.20
4.05 ± 0.77
14.62 ± 0.75

−
-3.50 ± 0.09
-1.24 ± 0.55
0.17 ± 1.03
0.70 ± 0.21

−
11.35 ± 0.67
145.90 ± 20.89
1.76 ± 0.95
1.66 ± 0.24

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.00 ± 0.18
19.65 ± 0.43
23.40 ± 0.08
21.47 ± 0.08
31.86 ± 0.95

−
1.65 ± 0.61
4.79 ± 0.04
3.47 ± 0.10
13.86 ± 0.77

−
5.80 ± 0.29
9.09 ± 0.25
0.75 ± 0.35
1.46 ± 0.18

−
57.89 ± 11.50
562.72 ± 94.18
1.79 ± 0.42
2.79 ± 0.35

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.50 ± 0.29
19.06 ± 0.02
22.95 ± 0.36
18.94 ± 0.26
29.17 ± 0.04

−
0.56 ± 0.27
4.45 ± 0.65
0.44 ± 0.03
10.68 ± 0.25

−
-6.88 ± 0.04
10.04 ± 0.15
3.79 ± 0.29
4.64 ± 1.21

−
118.00 ± 3.49
1064.11 ± 110.65
14.37 ± 2.80
44.56 ± 26.12

Day 7
Day 10

BMP2 + SU5402 (10 µM)

BMP2 + SU5402 (5 µM)

Day 7

Day 21

Osteocalcin
Dspp

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.06 ± 0.49
28.01 ± 0.73
34.04 ± 0.22
24.34 ± 0.21
34.79 ± 0.73

−
8.95 ± 1.22
14.96 ± 0.27
5.28 ± 0.70
15.73 ± 0.24

−
-1.51 ± 0.91
-0.49 ± 0.23
-1.05 ± 0.96
-0.42 ± 0.72

−
0.50 ± 0.25
0.73 ± 0.12
0.71 ± 0.37
0.94 ± 0.40

Gapdh
Bsp
Dmp1
Osteocalcin

18.21 ± 0.24
21.75 ± 0.11
25.41 ± 0.17
22.05 ± 0.56

−
3.54 ± 0.13
7.20 ± 0.07
3.85 ± 0.80

−
3.91 ± 0.19
7.29 ± 0.43
0.38 ± 1.05

−
15.21 ± 1.94
171.09 ± 48.49
2.06 ± 1.12
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32.71 ± 0.86

14.50 ± 0.62

0.81 ± 0.33

1.85 ± 0.42

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

17.88 ± 0.22
19.24 ± 0.52
23.57 ± 0.01
21.94 ± 0.17
32.78 ± 0.22

−
1.36 ± 0.29
5.69 ± 0.21
4.06 ± 0.39
14.90 ± 0.45

−
6.08 ± 0.02
8.80 ± 0.71
0.16 ± 0.14
0.41 ± 0.51

−
67.61 ± 1.02
558.14 ± 238.04
1.14 ± 0.11
1.50 ± 0.49

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.43 ± 0.20
18.96 ± 0.22
23.19 ± 0.21
19.26 ± 0.89
30.03 ± 0.10

−
0.53 ± 0.41
4.75 ± 0.41
0.83 ± 0.70
11.60 ± 0.29

−
6.91 ± 0.10
9.74 ± 0.13
3.40 ± 0.44
3.71 ± 1.25

−
120.61 ± 8.00
856.01 ± 53.07
11.49 ± 3.30
24.27 ± 14.43

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

18.39 ± 0.12
29.21 ± 0.20
34.29 ± 0.04
24.35 ± 0.40
37.50 ± 1.77

−
10.82 ± 0.32
15.90 ± 0.17
5.96 ± 0.52
19.11 ± 1.89

−
-3.38 ± 0.01
-1.41 ± 0.23
-1.74 ± 0.78
N.D.

−
0.10 ± 0.001
0.40 ± 0.09
0.39 ± 0.18
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.00 ± 0.37
22.06 ± 0.05
25.84 ± 0.16
22.26 ± 0.29
32.84 ± 0.97

−
4.06 ± 0.42
7.84 ± 0.20
4.26 ± 0.65
14.84 ± 0.61

−
3.38 ± 0.10
6.65 ± 0.30
-0.03 ± 0.91
0.47 ± 0.35

−
10.44 ± 0.71
104.92 ± 20.84
1.39 ± 0.70
1.47 ± 0.34

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.38 ± 0.10
20.46 ± 0.05
24.27 ± 0.33
22.20 ± 0.13
33.50 ± 0.47

−
2.08 ± 0.15
5.89 ± 0.43
3.82 ± 0.03
15.12 ± 0.38

−
5.36 ± 0.17
8.60 ± 0.07
0.41 ± 0.23
0.20 ± 0.59

−
41.62 ± 4.75
390.20 ± 19.09
1.36 ± 0.21
1.34 ± 0.49

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

18.90 ± 0.36
19.28 ± 0.05
23.45 ± 0.02
19.56 ± 0.27
30.41 ± 0.34

−
0.38 ± 0.41
4.56 ± 0.38
0.66 ± 0.09
11.52 ± 0.69

−
7.06 ± 0.10
9.93 ± 0.16
3.56 ± 0.35
3.80 ± 1.65

−
134.02 ± 8.87
983.64 ± 80.26
12.50 ± 2.91
36.51 ± 23.86

BMP2 + SU5402 (20 µM)

Day 7

Dspp

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day 10.
N.D. = not detected.
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Table 20. Concentration-dependent effects of early and limited exposure to SU5402 in
combination with BMP2 on intensity of BSP-GFP transgene in primary dental pulp
cultures.
Day of
culture

Epifluorescence
intensity

Fold change

7

793.00 ± 7.35

1

10

982.00 ± 38.28

1

14

1343.00 ± 139.82

1

21

2736.00 ± 173.58

1

7

349.00 ± 2.68

~0.44

10

758.00 ± 14.11

~0.76

14

1508.00 ± 47.16

~1.12

21

2647.00 ± 72.24

~0.97

7

380.00 ± 26.06

~0.48

10

758.00 ± 14.11

~0.76

14

1516.00 ± 65.20

~1.13

21

2565.00 ± 103.82

~0.97

7

351.00 ± 3.62

~0.44

10

749.00 ± 3.15

~0.76

14

1466.00 ± 117.33

~1.09

21

2555.00 ± 97.75

~0.93

7

351.00 ± 2.95

~0.44

10

739.00 ± 0.75

~0.75

14

1392.00 ± 124.50

~1.04

21

2511.00 ± 124.41

~0.92

10
20

BMP2 + SU5402 (µM)

5

BMP2

Control

Treatment

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by the control value for each time point.
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Table 21. Concentration-dependent effects of early and limited exposure to SU5402 in
combination with BMP2 on intensity of DMP1-mCherry transgene in primary dental pulp
cultures.
Day of
culture

Epifluorescence
intensity

Fold change

7

93.00 ± 6.27

1

10

253.00 ± 26.47

1

14

1713.00 ± 58.30

1

21

2452.00 ± 65.48

1

7

29.00 ± 2.66

~0.31

10

164.00 ± 17.30

~0.65

14

1484.00 ± 93.86

~0.87

21

1958.00 ± 71.43

~0.80

7

20.00 ± 6.34

~0.21

10

196.00 ± 48.51

~0.78

14

1628.00 ± 91.78

~0.95

21

1975.00 ± 105.13

~0.80

7

23.00 ± 6.91

~0.25

10

230.00 ± 48.38

~0.91

14

1733.00 ± 109.15

~1.01

21

2037.00 ± 96.36

~0.84

7

24.00 ± 7.56

~0.26

10

231.00 ± 51.48

~0.91

14

1773.00 ± 109.15

~1.03

21

2046.00 ± 86.65

~0.83

10
20

BMP2 + SU5402 (µM)

5

BMP2

Control

Treatment

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by the control value for each time point.
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Table 22. Concentration-dependent effects of early and limited exposure to noggin on
intensity of Xylenol Orange staining in primary dental pulp cultures.

200
300

Noggin (ng/ml)

100

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

165.00 ± 16.04

1

14

390.00 ± 38.69

1

21

841.00 ± 35.34

1

7

N.D.

–

10

88.00 ± 11.48

~0.53

14

266.00 ± 43.10

~0.68

21

798.00 ± 23.12

~1.00

7

N.D.

–

10

83.00 ± 10.81

~0.50

14

246.00 ± 34.95

~0.63

21

794.00 ± 37.56

~0.94

7

N.D.

–

10

81.00 ± 10.11

~0.49

14

231.00 ± 48.18

~0.59

21

738.00 ± 81.27

~0.88

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent noggin
value divided by the control value for each time point.
N.D. = not detected.
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CT

ΔCT

-ΔΔCT

Fold change

19.56 ± 0.27
26.15 ± 0.15
29.59 ± 0.41
22.05 ± 0.82
38.76 ± 0.72

−
6.60 ± 0.39
10.32 ± 0.24
2.49 ± 0.66
19.21 ± 0.62

−
0
0
0
N.D.

−
1
1
1
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.44 ± 0.31
20.32 ± 0.35
20.62 ± 0.69
19.90 ± 0.56
29.39 ± 1.60

−
0.88 ± 0.31
1.35 ± 0.38
0.46 ± 0.77
9.95 ± 1.57

−
5.72 ± 0.09
8.98 ± 0.15
2.04 ± 0.56
0

−
53.09 ± 3.20
511.84 ± 68.15
5.48 ± 2.22
1

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.56 ± 0.23
18.55 ± 0.11
20.07 ± 0.46
18.93 ± 0.75
27.36 ± 1.28

−
-1.01 ± 0.21
0.75 ± 0.39
-0.63 ± 0.63
7.80 ± 1.21

−
7.60 ± 0.23
9.58 ± 0.34
3.12 ± 0.08
2.15 ± 0.52

−
204.51 ± 31.37
824.14 ± 201.45
8.76 ± 0.58
5.54 ± 1.64

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.82 ± 0.05
18.03 ± 0.45
19.50 ± 0.37
17.91 ± 0.64
26.41 ± 1.38

−
-1.79 ± 0.44
-0.31 ± 0.41
-1.91 ± 0.63
6.59 ± 1.35

−
8.39 ± 0.08
10.64 ± 0.16
4.41 ± 0.26
3.36 ± 0.40

−
337.29 ± 19.16
1623.12 ± 228.69
22.84 ± 5.60
11.62 ± 2.32

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.99 ± 0.46
27.26 ± 0.42
30.86 ± 0.31
23.42 ± 1.29
39.93 ± 0.05

−
6.60 ± 0.39
11.42 ± 0.44
3.42 ± 0.98
19.94 ± 0.44

−
-0.91 ± 0.19
-1.03 ± 0.84
-0.75 ± 0.10
N.D.

−
0.55 ± 0.07
0.57 ± 0.30
0.60 ± 0.05
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.49 ± 0.51
20.86 ± 0.54
20.41 ± 0.03
21.32 ± 0.75
32.07 ± 2.91

−
0.88 ± 0.31
1.54 ± 0.02
1.83 ± 0.18
12.58 ± 2.63

−
4.99 ± 0.19
8.86 ± 0.01
0.85 ± 0.59
-2.02 ± 0.78

−
32.72 ± 4.49
480.36 ± 123.86
2.20 ± 0.78
0.36 ± 0.17

Gapdh
Bsp
Dmp1

19.37 ± 0.31
19.11 ± 0.41
19.39 ± 0.59

−
-1.01 ± 0.31
0.35 ± 0.26

−
6.63 ± 0.30
10.05 ± 0.10

−
105.72 ± 23.79
1061.86 ± 99.32

Noggin (100 ng/ml)

Day 7

Control

Day 7

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 14

Table 23. Concentration-dependent effects of early and limited exposure to noggin on the
expression of markers of mineralization and odontoblast differentiation in primary dental
pulp cultures.
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19.60 ± 1.12
28.91 ± 1.86

0.23 ± 0.97
9.54 ± 1.90

2.44 ± 0.13
1.02 ± 0.67

5.49 ± 0.57
2.80 ± 1.27

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.61 ± 0.21
17.90 ± 0.32
19.81 ± 0.86
18.37 ± 0.99
27.53 ± 1.59

−
-1.79 ± 0.44
0.21 ± 0.42
-1.25 ± 1.13
7.91 ± 1.75

−
8.07 ± 0.15
10.19 ± 0.02
3.92 ± 0.27
2.64 ± 0.25

−
273.86 ± 29.98
1166.42 ± 17.50
15.89 ± 3.18
6.52 ± 1.11

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.56 ± 0.28
28.24 ± 0.66
31.95 ± 0.48
23.68 ± 1.87
40.00 ± 0.00

−
8.30 ± 0.51
12.52 ± 0.51
3.74 ± 0.92
20.06 ± 0.41

−
-1.94 ± 0.42
-2.12 ± 0.91
-1.07 ± 0.18
N.D.

−
0.30 ± 0.08
0.29 ± 0.15
0.49 ± 0.07
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.04 ± 0.16
20.63 ± 0.25
19.85 ± 0.73
20.49 ± 0.11
32.14 ± 2.78

−
1.59 ± 0.39
0.86 ± 0.39
1.44 ± 0.31
13.10 ± 2.93

−
4.77 ± 0.39
9.54 ± 0.19
1.23 ± 0.58
-2.48 ± 1.05

−
30.21 ± 6.97
743.19 ± 4.19
2.91 ± 1.20
0.31 ± 0.12

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.00 ± 0.31
18.73 ± 0.25
19.58 ± 0.46
18.72 ± 0.87
29.32 ± 2.04

−
-0.28 ± 0.33
0.96 ± 0.31
-0.28 ± 0.71
10.32 ± 2.02

−
6.64 ± 0.16
9.44 ± 0.07
2.96 ± 0.20
0.24 ± 0.84

−
101.48 ± 10.52
695.28 ± 45.04
8.00 ± 1.37
1.87 ± 0.94

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.37 ± 0.09
17.73 ± 0.26
20.03 ± 0.77
18.92 ± 1.11
27.42 ± 1.61

−
-1.64 ± 0.25
0.57 ± 0.67
-0.45 ± 1.21
8.05 ± 1.68

−
8.01 ± 0.23
9.82 ± 0.19
3.12 ± 0.25
2.50 ± 0.29

−
267.00 ± 40.15
922.92 ± 174.00
9.15 ± 2.09
5.97 ± 1.04

Day 7
Day 10

Noggin (300 ng/ml)

Noggin (200 ng/ml)

Day 7

Day 21

Osteocalcin
Dspp

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

20.44 ± 0.76
28.24 ± 0.66
31.96 ± 0.56
24.95 ± 1.30
40.00 ± 0.00

−
8.28 ± 0.83
12.44 ± 0.47
4.51 ± 0.62
19.56 ± 0.76

−
-1.91 ± 0.40
-2.05 ± 0.87
-1.83 ± 0.29
N.D.

−
0.29 ± 0.07
0.29 ± 0.15
0.30 ± 0.07
N.D.

Gapdh
Bsp
Dmp1
Osteocalcin

19.31 ± 0.25
20.78 ± 0.25
19.90 ± 0.45
21.04 ± 0.18

−
1.47 ± 0.32
0.83 ± 0.13
1.73 ± 0.13

−
4.89 ± 0.32
9.56 ± 0.08
0.95 ± 0.71

−
31.84 ± 6.02
769.00 ± 142.59
2.57 ± 1.09
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Dspp

32.33 ± 2.37

13.03 ± 2.46

-2.48 ± 1.05

0.31 ± 0.12

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.48 ± 0.18
18.77 ± 0.42
19.40 ± 0.05
19.16 ± 0.95
30.00 ± 2.49

−
-0.71 ± 0.29
0.12 ± 0.08
-0.32 ± 0.83
10.51 ± 2.46

−
7.07 ± 0.60
10.28 ± 0.34
3.00 ± 0.19
0.04 ± 0.53

−
166.94 ± 52.41
1308.15 ± 418.91
8.21 ± 1.43
1.27 ± 0.47

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.50 ± 0.17
18.10 ± 0.33
19.84 ± 0.52
19.05 ± 0.94
27.53 ± 1.43

−
-1.40 ± 0.20
0.22 ± 0.81
-0.46 ± 0.86
8.03 ± 1.37

−
7.76 ± 0.44
10.18 ± 0.29
3.13 ± 0.08
2.52 ± 0.60

−
244.44 ± 60.60
1204.21 ± 335.42
8.79 ± 0.62
7.10 ± 2.11

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day 10.
N.D. = not detected.
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Table 24. Concentration-dependent effects of early and limited exposure to noggin on
intensity of BSP-GFP transgene in primary dental pulp cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

747.00 ± 28.84

1

10

1029.00 ± 27.05

1

14

1334.00 ± 40.70

1

21

2870.00 ± 125.90

1

7

442.00 ± 66.84

~0.59

10

1029.00 ± 19.46

1

14

1182.00 ± 42.43

~0.89

21

2612.00 ± 44.88

~0.91

7

375.00 ± 40.03

~0.50

10

995.00 ± 11.84

~0.97

14

1171.00 ± 62.70

~0.88

21

2533.00 ± 94.41

~0.88

7

274.00 ± 0.73

~0.37

10

999.00 ± 12.25

~0.97

14

1209.00 ± 89.00

~0.91

21

2539.00 ± 39.98

~0.88

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 25. Concentration-dependent effects of early and limited exposure to noggin on
intensity of DMP1-mCherry transgene in primary dental pulp cultures.

20
50

BMP2 (ng/ml)

10

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

88.00 ± 12.09

1

10

210.00 ± 21.30

1

14

1580.00 ± 137.08

1

21

2353.00 ± 201.53

1

7

52.00 ± 8.06

~0.59

10

276.00 ± 19.38

~1.31

14

1737.00 ± 202.15

~1.10

21

2272.00 ± 83.39

~0.97

7

57.00 ± 6.62

~0.64

10

219.00 ± 27.57

~1.05

14

1543.00 ± 183.03

~0.98

21

2200.00 ± 134.53

~0.94

7

56.00 ± 6.84

~0.63

10

238.00 ± 1.52

~1.13

14

1657.00 ± 154.40

~1.05

21

2196.00 ± 7.22

~0.93

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent BMP2 value
divided by the control value for each respective time point.
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Table 26. Concentration-dependent effects of early and limited exposure to noggin in
combination with FGF2 on intensity of Xylenol Orange staining in primary dental pulp
cultures.

200
300

FGF2 + Noggin (ng/ml)

100

FGF2

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

165.00 ± 16.04

1

14

390.00 ± 38.69

1

21

841.00 ± 35.34

1

7

N.D.

–

10

178.00 ± 15.23

~1.08

14

395.00 ± 22.42

~1.01

21

1264.00 ± 115.00

~1.52

7

N.D.

–

10

178.00 ± 18.18

~1.08

14

404.00 ± 34.31

~1.04

21

922.00 ± 25.20

~1.10

7

N.D.

–

10

168.00 ± 20.57

~1.02

14

387.00 ± 31.24

~0.99

21

780.00 ± 8.82

~0.93

7

N.D.

–

10

117.00 ± 22.76

~0.71

14

274.00 ± 49.85

~0.70

21

684.00 ± 17.61

~0.81

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by control value for each time point. N.D. = not detected.
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CT

ΔCT

-ΔΔCT

Fold change

19.56 ± 0.27
26.15 ± 0.15
29.59 ± 0.41
22.05 ± 0.82
38.76 ± 0.72

−
6.60 ± 0.39
10.32 ± 0.24
2.49 ± 0.66
19.21 ± 0.62

−
0
0
0
N.D.

−
1
1
1
N.D.

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.44 ± 0.31
20.32 ± 0.35
20.62 ± 0.69
19.90 ± 0.56
29.39 ± 1.60

−
0.88 ± 0.31
1.35 ± 0.38
0.46 ± 0.77
9.95 ± 1.57

−
5.72 ± 0.09
8.98 ± 0.15
2.04 ± 0.56
0

−
53.09 ± 3.20
511.84 ± 68.15
5.48 ± 2.22
1

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.56 ± 0.23
18.55 ± 0.11
20.07 ± 0.46
18.93 ± 0.75
27.36 ± 1.28

−
-1.01 ± 0.21
0.75 ± 0.39
-0.63 ± 0.63
7.80 ± 1.21

−
7.60 ± 0.23
9.58 ± 0.34
3.12 ± 0.08
2.15 ± 0.52

−
204.51 ± 31.37
824.14 ± 201.45
8.76 ± 0.58
5.54 ± 1.64

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.82 ± 0.05
18.03 ± 0.45
19.50 ± 0.37
17.91 ± 0.64
26.41 ± 1.38

−
-1.79 ± 0.44
-0.31 ± 0.41
-1.91 ± 0.63
6.59 ± 1.35

−
8.39 ± 0.08
10.64 ± 0.16
4.41 ± 0.26
3.36 ± 0.40

−
337.29 ± 19.16
1623.12 ± 228.69
22.84 ± 5.60
11.62 ± 2.32

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

20.44 ± 0.76
25.86 ± 0.43
21.85 ± 1.51
20.86 ± 0.90
29.63 ± 1.80

−
5.87 ± 1.00
2.59 ± 0.96
0.87 ± 0.29
9.64 ± 1.61

−
0.87 ± 0.51
7.50 ± 0.86
2.16 ± 0.21
1.71 ± 0.41

−
2.23 ± 0.84
214.44 ± 115.09
4.61 ± 0.74
3.64 ± 0.89

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.23 ± 0.22
20.15 ± 0.06
20.00 ± 0.38
19.23 ± 0.67
27.85 ± 1.30

−
0.92 ± 0.23
0.90 ± 0.02
-0.004 ± 0.71
8.62 ± 1.33

−
5.82 ± 0.48
9.19 ± 0.38
3.04 ± 0.14
2.73 ± 0.13

−
66.17 ± 19.80
585.63 ± 47.26
8.34 ± 1.01
6.70 ± 0.61

Gapdh
Bsp
Dmp1

19.53 ± 0.39
18.01 ± 0.12
18.86 ± 1.46

−
-1.53 ± 0.88
-0.41 ± 0.76

−
8.27 ± 0.41
10.50 ± 0.47

−
352.14 ± 109.20
1605.66 ± 692.87

FGF2 (20 ng/ml)

Day 7

Control

Day 7

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

Day 14

Table 27. Concentration-dependent effects of early and limited exposure to noggin in
combination with FGF2 on expression of markers of mineralization and odontoblast
differentiation in primary dental pulp cultures.
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19.39 ± 0.88
28.20 ± 1.16

-0.14 ± 0.80
6.67 ± 1.41

3.18 ± 0.24
4.68 ± 0.72

9.41 ± 1.76
35.67 ± 15.23

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

20.07 ± 0.02
18.53 ± 0.66
19.32 ± 0.001
18.29 ± 0.65
25.20 ± 1.24

−
-1.54 ± 0.67
-0.75 ± 0.49
-1.77 ± 0.66
5.13 ± 1.25

−
8.28 ± 0.35
10.84 ± 0.10
4.81 ± 0.11
6.22 ± 0.17

−
337.87 ± 73.42
1842.05 ± 176.72
28.28 ± 2.59
76.07 ± 9.60

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.74 ± 0.29
26.05 ± 0.37
26.65 ± 2.09
20.86 ± 0.66
36.70 ± 2.69

−
6.31 ± 0.55
7.19 ± 1.70
1.18 ± 0.32
16.97 ± 2.75

−
0.43 ± 0.06
2.90 ± 1.60
1.85 ± 0.40
-5.62 ± 1.53

−
1.35 ± 0.06
12.52 ± 10.08
4.03 ± 1.30
0.08 ± 0.06

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

20.14 ± 1.79
22.20 ± 1.24
20.01 ± 1.14
20.30 ± 2.17
28.89 ± 2.20

−
2.06 ± 0.07
1.28 ± 0.63
0.16 ± 1.14
8.75 ± 1.33

−
4.69 ± 0.56
8.81 ± 0.14
2.88 ± 0.49
2.60 ± 0.07

−
30.98 ± 8.59
478.66 ± 168.47
8.86 ± 4.01
6.08 ± 0.31

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.22 ± 0.24
19.52 ± 1.27
19.66 ± 1.10
20.74 ± 1.61
27.11 ± 1.35

−
0.30 ± 0.17
0.67 ± 0.80
1.52 ± 1.44
7.89 ± 1.41

−
6.44 ± 1.59
9.42 ± 0.50
1.51 ± 0.82
3.46 ± 0.51

−
243.16 ± 121.62
766.51 ± 345.54
4.08 ± 1.74
13.01 ± 3.96

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.83 ± 0.21
18.68 ± 0.17
19.04 ± 0.68
20.15 ± 1.14
26.87 ± 1.77

−
-1.15 ± 0.37
-0.66 ± 0.30
0.32 ± 1.15
7.04 ± 1.86

−
7.90 ± 0.50
10.75 ± 0.15
2.72 ± 0.52
4.31 ± 0.61

−
287.95 ± 103.11
1742.81 ± 248.18
7.89 ± 3.17
25.84 ± 10.52

Day 7
Day 10

FGF2 + noggin (200 ng/ml)

FGF2 + noggin (100 ng/ml)

Day 7

Day 21

Osteocalcin
Dspp

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.77 ± 0.44
26.25 ± 0.32
27.69 ± 1.08
22.79 ± 1.08
37.18 ± 2.29

−
6.47 ± 0.61
8.38 ± 0.62
2.01 ± 0.63
17.40 ± 2.33

−
0.27 ± 0.12
-1.70 ± 0.52
-1.02 ± 0.30
6.05 ± 1.20

−
1.22 ± 0.11
3.47 ± 1.21
2.16 ± 0.57
0.03 ± 0.01

Gapdh
Bsp
Dmp1
Osteocalcin

19.46 ± 0.59
22.02 ± 0.97
20.04 ± 1.22
19.90 ± 1.12

−
2.55 ± 0.63
1.06 ± 0.28
0.44 ± 1.05

−
4.18 ± 1.09
9.02 ± 0.13
2.59 ± 0.41

−
33.21 ± 15.05
524.71 ± 70.06
6.91 ± 2.69
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30.97 ± 2.66

11.50 ± 2.42

0.16 ± 1.33

1.87 ± 0.72

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.59 ± 0.39
20.94 ± 1.44
19.80 ± 0.65
21.84 ± 1.76
28.24 ± 1.95

−
1.35 ± 0.77
0.65 ± 0.34
2.24 ± 1.40
8.64 ± 1.78

−
5.39 ± 1.59
9.43 ± 0.17
0.78 ± 0.77
2.70 ± 0.45

−
112.67 ± 65.05
700.91 ± 118.49
2.40 ± 1.06
7.61 ± 2.53

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.77 ± 0.23
18.76 ± 0.12
19.21 ± 0.61
20.15 ± 1.09
27.86 ± 2.19

−
-1.01 ± 0.35
-0.44 ± 0.16
0.37 ± 1.11
8.08 ± 2.28

−
7.76 ± 0.46
10.53 ± 0.04
2.66 ± 0.50
3.26 ± 0.95

−
254.28 ± 84.10
1488.25 ± 66.32
7.45 ± 2.69
18.88 ± 11.87

Gene
Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.97 ± 0.60
26.35 ± 0.38
28.42 ± 0.62
22.27 ± 0.98
37.44 ± 2.08

−
6.38 ± 0.65
8.87 ± 0.49
2.30. ± 0.61
17.47 ± 1.99

−
-0.36 ± 0.25
1.21 ± 0.40
0.72 ± 0.19
6.12 ± 0.87

−
1.34 ± 0.21
2.41 ± 0.65
1.70 ± 0.27
0.02 ± 0.00

Day 10

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.36 ± 0.55
20.76 ± 0.27
19.83 ± 1.41
19.72 ± 1.19
32.40 ± 3.23

−
1.39 ± 0.20
0.71 ± 0.87
0.35 ± 1.19
13.04 ± 3.13

−
5.34 ± 0.28
9.37 ± 0.54
2.67 ± 0.53
-1.69 ± 2.03

−
42.9 ± 7.34
763.88 ± 376.01
7.93 ± 3.74
1.19 ± 0.52

Day 14

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.72 ± 0.18
19.43 ± 0.34
20.25 ± 0.52
19.99 ± 0.32
30.21 ± 2.82

−
-0.29 ± 0.16
0.71 ± 0.73
0.27 ± 0.24
10.48 ± 2.64

−
7.03 ± 0.17
9.37 ± 0.45
2.76 ± 0.43
0.86 ± 1.41

−
134.37 ± 16.46
730.74 ± 306.07
7.75 ± 2.80
4.68 ± 2.63

Day 21

Gapdh
Bsp
Dmp1
Osteocalcin
Dspp

19.62 ± 0.09
18.94 ± 0.26
19.16 ± 0.74
20.85 ± 1.23
28.09 ± 2.21

−
-0.67 ± 0.24
-0.35 ± 0.76
1.23 ± 1.13
8.47 ± 2.14

−
7.42 ± 0.53
10.44 ± 0.47
1.79 ± 0.49
2.87 ± 0.81

−
207.22 ± 67.49
1540.75 ± 666.16
4.14 ± 1.68
11.67 ± 6.12

FGF2 + noggin (300 ng/ml)

Day 7

Dspp

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day
10. N.D. = not detected.
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Table 28. Concentration-dependent effects of early and limited exposure to noggin in
combination with FGF2 on intensity of BSP-GFP transgene in primary dental pulp
cultures.

200
300

FGF2 + Noggin (ng/ml)

100

FGF2

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

747.00 ± 28.84

1

10

1029.00 ± 27.05

1

14

1334.00 ± 40.70

1

21

2870.00 ± 125.90

1

7

919.00 ± 11.02

~1.23

10

1039.00 ± 55.00

~1.01

14

1296.00 ± 71.29

~0.97

21

2805.00 ± 39.98

~0.98

7

835.00 ± 36.56

~1.12

10

939.00 ± 62.52

~0.91

14

1305.00 ± 41.69

~0.98

21

2538.00 ± 188.05

~0.88

7

823.00 ± 30.98

~1.08

10

916.00 ± 51.44

~0.89

14

1233.00 ± 59.76

~0.92

21

2490.00 ± 185.69

~0.87

7

792.00 ± 28.90

~1.06

10

867.00 ± 68.48

~0.84

14

1111.00 ± 73.94

~0.83

21

26432.00 ± 145.8

~0.92

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by the control value for each time point.
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Table 29. Concentration-dependent effects of early and limited exposure to noggin in
combination with FGF2 on intensity of DMP1-mCherry transgene in primary dental pulp
cultures.

200
300

FGF2 + Noggin (ng/ml)

100

FGF2

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

88.00 ± 12.09

1

10

210.00 ± 21.30

1

14

1580.00 ± 137.08

1

21

2353.00 ± 201.53

1

7

212.00 ± 22.62

~2.41

10

427.00 ± 108.21

~2.04

14

1599.00 ± 37.87

~1.01

21

2636.00 ± 158.17

~1.12

7

93.00 ± 1.05

~1.05

10

355.00 ± 68.74

~1.69

14

1438.00 ± 91.22

~0.91

21

2647.00 ± 113.05

~1.12

7

74.00 ± 0.78

~0.83

10

305.00 ± 48.87

~1.46

14

1397.00 ± 87.51

~0.88

21

2448.00 ± 209.22

~1.04

7

61.00 ± 1.44

~0.69

10

330.00 ± 63.03

~1.57

14

1497.00 ± 101.17

~0.95

21

2304.00 ± 352.15

~0.98

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent value
obtained in a treated culture divided by the control value for each time point.
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